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  
	
 Postterm birth is a preventable cause of perinatal mortality and severe morbidity. This 
review examined the association between maternal BMI and postterm birth at ≥42 and ≥41 weeks’ 
gestation. 
 Six databases, reference lists and citations were searched MayNovember 2015. 
Observational studies published in English since 1990 were included. Linear and nonlinear dose
response metaanalyses were conducted using random effects models. Sensitivity analyses assessed 
robustness of the results. Metaregression and subgroup metaanalyses explored heterogeneity. 
Obesity classes were defined as I (30.034.9kg/m2), II (35.039.9kg/m2), and III (≥40kg/m2; IIIa 40.0
44.9kg/m2, IIIb ≥45.0kg/m2).  
	 Searches identified 16,375 results; 39 studies met the inclusion criteria (n=4,143,700 births). 
A nonlinear association between maternal BMI and births ≥42 weeks was identified, ORs and 95% CIs 
for obesity classes IIIIb were 1.42 (1.271.58), 1.55 (1.371.75), 1.65 (1.441.87) and 1.75 (1.502.04) 
respectively. BMI was linearly associated with births ≥41 weeks: OR 1.13 (95% CI 1.051.21) for each 5 
unit increase in BMI.  

	
 The strength of the association between BMI and postterm birth increases with 
increasing BMI. Odds are greatest for births ≥42 weeks among class III obesity. Targeted interventions 
to prevent the adverse outcomes associated with postterm birth should consider the difference in risk 
between obesity classes. 
 
 
 
BMI body mass index 
OR odds ratio 
CI confidence interval 
IQR inter quartile range 
RR relative risk 
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
	

Postterm birth is a preventable cause of intrauterine death, stillbirth, neonatal and infant death14. 
Postterm birth contributes to severe morbidities for the mother and child, including macrosomia, 
shoulder dystocia, birth injury, fourth degree perineal laceration, fetal compromise, antenatal and 
postpartum haemorrhage, fetal dysmaturity, labour >24 hours, and newborn respiratory distress 
syndrome1, 57. There is emerging evidence that primiparous women who deliver postterm have an 
increased risk of developing Type 2 Diabetes in later life8. Costly obstetric and neonatal interventions 
associated with postterm birth include caesarean section, induction of labour, operative vaginal 
delivery, close fetal monitoring beyond term, ventilator use and neonatal intensive care admission1, 7, 9. 
The risks associated with postterm birth have historically been underestimated due to selfreported 
assessment of gestational age relying on last menstrual period. This selfreport assessment over
estimates postterm prevalence, resulting in an underestimate of the risks of “true” postterm birth due 
to lowerrisk “term” births being misclassified as postterm1, 4, 6. Current widespread use of ultrasound 
scan technology provides a more accurate estimation of gestational age10, and allows exploration of the 
“true” postterm risks.  
 
Maternal obesity (i.e. prepregnancy body mass index (BMI) ≥30kg/m2) impacts on daily clinical 
practice due to the international rise in its prevalence, and the complexity of its comorbidities. Maternal 
obesity is a complex condition strongly associated with socioeconomic status and ethnicity 
inequalities11, 12, making it a public health priority in addition to being a priority area for clinical practice. 
For example, socioeconomic status varies between obesity classes, and pregnant women in the 
highest obesity class (class III, BMI≥40kg/m2) are significantly more likely to reside in deprived 
locations (OR 4.7, 95% CI 3.26.9) compared with women in obesity class I (BMI 30.034.9kg/m2)(OR 
2.2, 95% CI 2.12.3)11. Disparities are also seen with maternal employment status. Pregnant women 
with a BMI in class I are more likely to be employed, while those in class III are more likely to be 
unemployed11. Obesityassociated adverse pregnancy outcomes for the mother and child include 
poorer mental health13, gestational diabetes14, congenital anomalies15, and perinatal mortality2, 16. Pre
pregnancy weight is the most significant modifiable risk factor for stillbirth, with up to 100% increased 
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risk for women with obesity22. There is increasing evidence that maternal BMI influences gestational 
age at delivery. Robust metaanalysis data demonstrates the relationship between BMI and preterm 
birth17, 18. Despite published studies exploring the association between maternal BMI and postterm 
birth1921, there is a lack of robust evidence from metaanalyses. 
 
Both maternal obesity and postterm birth are preventable, and therefore warrant intervention to 
prevent associated adverse outcomes. Challenges to investigating maternal obesity and postterm birth 
include interventions to expedite birth, such as induction of labour and caesarean section, interrupting 
the natural gestation trajectory. There are differences in the definitions used to classify postterm in 
existing literature, including pregnancies progressing beyond 40, 41, or 42 weeks gestation 4, 6. 
Although there is evidence of significantly increased risks for each definition of postterm beyond 40 
weeks 22, the greatest risk is among the gestations >42 weeks for most adverse outcomes 9. The 
terminology postterm and prolonged pregnancy are also used interchangeably to describe gestational 
ages beyond term 4.  
 
Investigation of the association between maternal obesity and postterm birth adds additional 
complexity. Maternal obesity is associated with a significantly increased risk of developing the 
comorbidities which lead to early intervention and disrupt the natural pregnancy trajectory, including 
gestational diabetes and preeclampsia14, 22. In addition, the BMI definitions used to categorise maternal 
weight status are used inconsistently, contributing to difficulty of interpretation when making direct 
comparisons of studies. The World Health Organisation criteria for categorising BMI are <18.5kg/m2 
(underweight), 18.524.9kg/m2 (recommended weight), 25.029.9kg/m2 (overweight), and >30.0kg/m2 
(obese); with further obesity subclasses of class I 30.034.9kg/m2, class II 35.039.9kg/m2, and class III 
>40kg/m2 obesity23. For Asian populations, the BMI criteria are reduced (recommended weight 18.5
23kg/m2, overweight 2327.5kg/m2, and obese >27.5kg/m2) due to increased risk of metabolic diseases 
at a lower BMI24. However, the Asianspecific definitions for weight status are not consistently adopted 
internationally in research or clinical guidelines. 
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Overcoming the methodological challenges to establish the relationship between BMI and postterm 
birth is important to inform strategies for preventing associated adverse outcomes, such as perinatal 
mortality and severe morbidity. Additionally, identification of the doseresponse association would 
inform preconception and antenatal healthcare planning, practice and guidelines such as risk 
communication and shared decision making for intervention options for targeted groups of women 
based on BMI. This systematic review and metaanalyses aimed to establish the strength of the 
association between maternal obesity and postterm birth. It specifically investigated the dose
response association between BMI and postterm birth, taking into consideration the methodological 
challenges, confounding and sources of heterogeneity in the existing research.    
 

Search strategies for systematic reviews of observational epidemiological studies require multiple 
components as database searches alone have been shown to only identify up to half of the relevant 
literature25. Systematic exclusion of studies through following an inadequate search strategy increases 
the risk of publication bias. Therefore a six stage search strategy was followed in an attempt to limit the 
effect of publication bias arising from searching literature databases alone. 
Stage 1: Databases were searched using keywords and study filters for nonRCT studies. Restrictions 
to human studies were included. Search terms and subject headings were developed for MEDLINE 
(fig. 1), and translated across four additional databases: British Nursing Index, CINAHL, Embase, and 
PsycInfo (fig. S1).  
Stage 2: The reference lists of all included studies, and all related systematic reviews identified in stage 
1, were hand searched. 
Stage 3: Citation searches for all included studies were performed using Google Scholar citations 
function.  
Stage 4: Authors of relevant published abstracts were contacted to identify if there had been 
subsequent full publication of studies. 
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Stage 5: Any additional studies identified in stages 24 were subject to further reference list and citation 
searching. Stages 25 continued until no further new studies were identified. 
Stage 6: Authors of included studies were contacted for additional data when required for inclusion in 
the metaanalyses.  
 
Inclusion criteria were peer reviewed full studies (i.e. not abstracts, editorials etc), published in the 
English language, since 1st January 1990. Studies had to report both the exposure variable (maternal 
weight status) and the outcome variable (postterm birth). The six stage search strategy was carried out 
between May and November 2015. Screening titles, abstracts and full papers for inclusion in the review 
was carried out by two researchers independently. Data extraction and quality assessment were also 
carried out independently by two researchers using a standardised protocol for data extraction (table 
S1), and the NewcastleOttawa scale for cohort studies for quality assessment (fig S2). Independent 
extractions and assessments were combined and agreed. A third researcher was available for any 
disagreements (not required).  
  
In circumstances where there were missing or unclear definitions for the exposure or outcome 
variables, missing frequency data, the authors were contacted for clarification. If authors did not 
respond to the request for further information after follow up email requests, or if the authors could not 
be contacted for any reason, then assumptions about the definitions were made based on the 
information provided in the papers. For example, if the study described that they had compared post
term (defined as ≥42 weeks) and preterm (defined as <37 weeks) with term (undefined), then the 
assumption was made that term was defined as the gestational age between the reported post and 
preterm (37 to 41+6 weeks). Alternative methods of making assumptions included searching for 
definitions in papers that the authors had referenced in relation to gestational age or BMI, and 
searching for any publications by the same authors on a similar topic where they had defined the 
variables. In the absence of any information to inform our assumptions following these methods, the 
terminology used by the authors was used to define the exposure and outcomes variables. For 
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example, if the authors used the term “normal BMI” then the WHO criteria of 18.524.9 kg/m2 was 
assumed.  
 
For the purposes of this systematic review, we categorised postterm birth into two outcome variables 
which were analysed separately. The primary outcome was postterm birth ≥42 weeks gestation as this 
gestation incurs the greatest risk associated with postterm birth, and the secondary outcome was post
term birth ≥41 weeks gestation as this gestation also has increased risk but to a lesser extent than 42 
weeks. Doseresponse metaanalyses were conducted to investigate the association between maternal 
BMI and both outcomes. The studyspecific linear trends (odds ratios (ORs) for continuous BMI 
assuming linearity) were derived using the method by Greenland and Longnecker26. This method 
requires the ORs with confidence intervals (CIs) for at least two exposure categories (including the 
reference group), and the number of cases and participants in each exposure category. If the adjusted 
ORs and CIs were not available, the respective unadjusted parameters were derived from the data, 
and used in the metaanalysis. To assess the effect of including adjusted and unadjusted ORs in the 
metaanalysis, subgroup metaanalyses were performed with the studies that reported both adjusted 
and unadjusted ORs (or provided data to enable unadjusted ORs to be calculated), and the statistical 
significance and direction of the associations were compared. For each exposure category, the 
midpoint was calculated as the average of the lower and upper bound, and the respective OR was 
assigned to each midpoint. As the BMI midpoint was required for these analyses, upper and lower 
cutoffs were applied to open ended BMI categories in increments of 5 BMI units (e.g. for 
BMI<18.5kg/m2 a 5 BMI unit lower limit of 13.5kg/m2 was applied; the respective midpoint was 
16kg/m2). The regression coefficient for a change of 5 BMI units (log OR5BMI) is a function of the 
coefficient estimated when assuming a change of 1 BMI unit (log ORBMI), such that log OR5BMI = 5 x log 
ORBMI. The summary ORs were calculated using the random effects model by DerSimonian and 
Laird27. 
 
A twostage, randomeffects, nonlinear doseresponse metaanalysis28, 29 was also conducted to 
assess potential nonlinear associations, using cubic splines regression to model maternal BMI. The first 
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stage involved fitting a cubic spline model with two spline transformations, accounting for the 
correlation within each set of published ORs. The two regression coefficients were combined, and the 
variance/covariance matrices estimated for each study using a randomeffects metaanalysis. 
Nonlinearity was assessed by testing that the coefficient of the second spline was equal to zero30. This 
method required ORs with CIs to be available for at least three exposure (BMI) categories, as when 
only two categories are reported (e.g. recommended BMI and obese BMI), information on how the 
outcome behaves between the two categories is not available and nonlinearity cannot be assessed. 
Therefore, studies reporting data for only two BMI categories were excluded from the nonlinear 
analyses.  
 
Publication bias was tested for using Eggers test31. A 2sided pvalue <0.05 was considered statistically 
significant. Sensitivity analyses were performed by systematically excluding one study at a time from 
the metaanalysis. Metaregression and subgroup metaanalyses were carried out to explore factors 
identified apriori as being potentially important sources of heterogeneity. Apriori clinical factors were 
the method of assessment of the exposure and outcome variables (maternal weight and gestational 
age at delivery), and consideration of the clinical confounders which impact on gestational age at 
delivery (induction of labour, elective caesarean section, parity, gestational diabetes, hypertension and 
preeclampsia). No studies were excluded from the overall metaanalysis based on methodological 
factors such as quality. However, methodological factors, includ ng quality as well as study size, 
geography, quality, age and duration of the data included, study design (e.g. retrospective or 
prospective, number of exposure categories, adjusted data), and how studies were identified for 
inclusion in the review were explored by metaregression and subgroup metaanalysis . Heterogeneity 
among studies was evaluated using the I2 statistic32 with a threshold of >75% representing 
considerable heterogeneity!!. The statistical analyses were conducted using Stata version 13.1. 
Studies which met the inclusion criteria but did not present data suitable for inclusion in the meta
analyses are summarised narratively. The systematic review was registered on the PROSPERO 
database (reference CRD42015014164).  
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	
Searches identified 16,375 studies, of which 39 met the inclusion criteria, giving a total population of 
4,143,700 births (fig. 2, table S2 for detailed information on screening). Of the included studies, 24 
(62%) were identified through database searches and 15 (38%) by searching reference lists and 
citations. Contacting authors of published abstracts did not identify any additional eligible studies. Of 
the 39 included studies, 26 reported data for postterm birth ≥42 weeks, and 14 reported ≥41 weeks 
(see table 1 for summary of included studies, Table S3 for additional detail). Some studies provided 
data for both definitions of postterm (table 1). Twenty studies were from Europe, five each from the 
USA and Middle East, four from Asia, three from Canada, and one each from South Africa and 
Australia. Most studies were published between 2005 and 2014 (n=33). Additional information was 
requested from the authors on definitions used (e.g. BMI or gestational age categories), or frequencies 
(e.g. number of cases or controls) for 34 studies (table S4). The quality of studies ranged from a score 
of one to eight, with a median quality score of four (table 1, and table S4 for detailed quality 
assessment results).  
 
There was negligible influence of using unadjusted or adjusted ORs in the analysis of either postterm 
birth categories with a difference in OR of 0.03 when comparing adjusted and unadjusted data from the 
same studies (fig. S3). Therefore, adjusted ORs were used when reported, and unadjusted ORs in the 
absence of adjusted data. One study used the Asian specific BMI reference criteria34. These data were 
transformed to represent the general population BMI criteria with no influence on the overall effect size 
(fig. S4). 
 
Nineteen studies reported data that could be pooled for metaanalysis of postterm birth ≥42 weeks, 
and 11 studies reported data for postterm birth ≥41 weeks (some studies reported multiple outcomes). 
Data from 10 studies could not be included in the metaanalysis and a narrative summary is provided 
for the results of these studies.  
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Metaanalyses of postterm birth ≥42 weeks gestation 
The 19 studies with data for ≥42 weeks metaanalysis, included 201,396 cases among 2,501,803 
pregnancies (8.1% incidence). In the doseresponse analysis, the OR for each 5 unit increase or 
decrease in BMI compared with the reference BMI midpoint (22kg/m2) was 1.19 (95% CI 1.121.26; 
heterogeneity I2=98.1%, p<0.001) (fig. 3a). There was evidence of a nonlinear association (p=0.002, 
table S6a, fig. 3b) with a statistically significant decrease in odds of births ≥42 weeks for underweight 
BMI compared with the reference group, and an increase for overweight and obese BMIs (table 2). The 
odds of birth ≥42 weeks increased within obesity classes, with 42%, 55%, 65% and 75% increased 
odds for BMI classes I, II, IIIa and IIIb respectively (table 2). There was no evidence of publication bias 
in the analyses of births ≥42 weeks (p=0.60, table S7). 
 
Metaanalyses of postterm birth ≥41 weeks gestation 
The 11 studies with data for the metaanalysis of births ≥41 weeks included 70,334 cases among 
444,706 pregnancies (15.8% incidence). In the doseresponse analysis, the OR for each 5 unit 
increase or decrease in BMI compared with the reference BMI midpoint was 1.13 (95% CI 1.051.21; 
heterogeneity I2=94%, p<0.001) (fig. 4a). Linearity of association between maternal BMI and birth ≥41 
weeks is not rejected (p=0.23, table S6b). Assuming a linear association, this suggests a statistically 
significant decrease in odds of births ≥41 weeks for underweight BMI compared with the reference 
group, and an increase for overweight and obese BMIs (table 2, fig. 4b). This increasing linear 
association was also observed within the obesity classes, although to a lesser extent than for births ≥42 
weeks (26%, 39%, and 52% increased odds for classes I, II, and III respectively) (table 2). There was 
no evidence of publication bias in the analyses of births ≥41 weeks (p=0.16, table S7). 
 
Sensitivity and heterogeneity analyses 
Sensitivity analyses did not show any significant influence on linearity of any individual studies in the 
linear analyses for either postterm categories (tables S8 and S9), or in the nonlinear analysis for births 
≥42 weeks (table S8). For births ≥41 weeks, the sensitivity analyses for the nonlinear model detected 
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that data from one study35 had an influence on linearity of the association between postterm birth and 
maternal BMI (table S9 and fig. S5). The inclusion of data from all studies visually appeared to be 
nonlinear (fig. S5); however, nonlinearity was not statistically significant (p=0.065, table S6c). When the 
data from this one study which was influencing linearity35 were removed, the results showed a linear 
trend (fig. 4b). 
 
Metaregression exploring potential sources of heterogeneity identified that adjusting for the number of 
BMI exposure categories had the greatest influence on overall heterogeneity for births ≥42 weeks (I2 
reduced by 22.2%, from 98.1 to 75.95%, table S10). Adjusting for additional variables in the meta
regression did not have a substantial impact on overall heterogeneity for either postterm outcomes. 
Subgroup metaanalyses for postterm birth ≥42 weeks, identified a significant reduction in 
heterogeneity (I2 <75%, p>0.05, ≥3 studies) in the following categories: having three or four exposure 
categories, sample size between 1,00010,000, controlling for induction of labour or caesarean 
delivery, and controlling for hypertension or preeclampsia (table S10). The most relevant influence on 
heterogeneity in the subgroup metaanalyses of births ≥41 weeks was having four exposure 
categories (table S11).    
 
Narrative summary of papers not included in the metaanalysis 
The 10 studies which had to be excluded from the metaanalyses due to a lack of comparable data for 
pooling included: two studies only reporting maternal weight and not BMI36, 37, five did not report 
frequency data for participants and/or cases of postterm birth21, 3841, and three did not have 
comparable BMI reference groups (one combined all nonobese42; one combined underweight and 
recommended weight43; and one combined recommended weight and overweight44). Of the ten studies 
not included in the metaanalyses, six found a significantly increased risk of postterm birth in obese 
women compared to the reference group21, 3740, 44, while four did not find a significantly increased 
association36, 4143 (table 3). 
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"	
 
This systematic review and metaanalysis of over 4 million births has identified a significantly increasing 
association between maternal BMI and postterm birth. This association increases in strength as BMI 
increases, with a substantial difference in effect size between obesity classifications: a difference of 
33% in odds of postterm birth ≥42 weeks, and 26% for ≥41 weeks when comparing obesity classes I 
and III. This substantial increase in postterm birth and associated risks for mothers in the highest 
obesity class presents a double burden of inequality. Women facing the greatest socioeconomic 
disadvantage11 also have the highest level of pregnancyrelated risk, confirming that maternal obesity is 
both a clinical and public health priority for the wellbeing of women and their babies.  
 
The mechanisms linking maternal BMI and postterm birth are not fully understood. The onset of labour 
involves mechanical and hormonal interactions between the mother, fetus and placenta. The exact 
causal pathways remain unclear and much of the evidence is based on animal models. This evidence 
suggests a number of potential mechanisms. Hormones are thought to play a key role in the pathway, 
including corticotrophinreleasing hormone, oestrogen, progesterone, prostaglandins and oxytocin45. 
Additionally, it is well established that women with obesity have increased inflammation, circulating 
leptin concentrations, insulin resistance, lipolysis, and dyslipidaemia. These metabolic abnormalities 
have been hypothesised to influence the onset of spontaneous or oxytocininduced labour and uterine 
contractility45. There is also evidence from one study in humans that shows that women with diabetes 
(including type 1 diabetes and gestational diabetes) had significantly reduced spontaneous myometrial 
contractility compared with women without diabetes, even after stimulation with oxytocin46. Uterine 
biopsies identified reduced calcium channel expression and signalling among women with diabetes, 
and the authors concluded that this was likely to account for the reduced contractility in addition to a 
small but significant difference in myometrial mass46. As obesity and diabetes are closely related, 
further exploration of myometrial contractility between women of different weight status’ could provide 
further evidence for causal mechanisms of postterm birth and obesity. 
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The heterogeneity in the relationship between degree of obesity and risk of postterm birth is an 
important message for researchers, practitioners and policy makers. The implication of using one 
criteria to define the obese population is an attenuation of the true risk for the higher obesity classes. 
Despite the differences between obesity classes, pregnancy outcome data is often reported for one 
obese category. When pregnancy outcomes are reported by obesity class, a similar pattern is often 
reported. For example, the odds of preterm birth were reported to increase twofold from 1.6 (95% CI 
1.41.8) for class I, to 3.0 (95% CI, 2.33.9) for class III obesity47. Similarly, the odds of GDM increased 
from 3.0 (95% CI 2.3 to 3.9) for class I, to 5.6 (95% CI 4.3 to 7.2) for class III obesity14. However, 
differentiating between obesity classes can be challenging. Although class III obesity is increasing at 
the most rapid rate over time11 it only represents approximately 1% of pregnancies in the UK11, and 4% 
in the USA12. For population data to be powered for statistical significance, the sample size needs to be 
sufficient to detect enough cases in each obesity class. Our subgroup metaanalyses suggests that 
100 cases of postterm birth ≥42 weeks, and 1000 cases for ≥41 weeks are required to detect 
significance, which may not always be feasible, even in nationallevel datasets. When obesity 
classifications have to be combined for statistical power, there should be cautious interpretation of the 
results reflecting “obesity” without consideration of the heterogeneous nature of obesity classifications. 
Additionally, the use of Asianspecific rather than general population BMI criteria should be considered 
in future research. Although we did not identify any impact of using either definition on postterm birth in 
this review, our analyses were limited as only one study had utilised the Asianspecific criteria. 
 
There are similar challenges with inconsistent use of postterm birth categories. Metaanalyses showed 
an increased association with maternal BMI and both postterm categories, and the highest odds for 
births ≥42 weeks. Although there is significantly increased risk for pregnancies progressing beyond 40 
weeks22, the greatest risk is in pregnancies with gestations >42 weeks9, particularly for perinatal 
mortality and severe morbidities which require obstetric and neonatal intervention. Studies which 
combine postterm birth categories are likely to underestimate the level of risk associated with maternal 
BMI. 
 
Page 18 of 106
World Obesity Journals
Obesity Reviews
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
15 
 
A key strength of this review is overcoming the methodological challenges of investigating postterm 
birth and maternal BMI. Analyses were performed throughout to explore the influence of 
methodological decisions, such as using unadjusted data and Asianspecific BMI categories. The 
conversion of categorical BMI was necessary due to limited reporting of directly comparable obesity 
categories: 17 studies combined data for obesity classes IIII19, 34, 35, 38, 4244, 4857; three reported obesity 
classes IIII separately5860; four combined obesity classes III20, 41, 61, 62; six combined classes IIIII39, 40, 
6366; seven had further inconsistent noncomparable categories such as combining overweight and 
obese36, 37, 6771; and two studies did not define their BMI categories21, 72. The possible groups to 
combine for categorical analyses would have been further reduced when applying additional analysis 
criteria such as the gestational age stratification, definition of the reference BMI group etc. Therefore 
the conversion to continuous BMI allowed direct comparison of more studies overall than would have 
been possible using a categorical metaanalyses. To aid the interpretation of continuous BMI analyses, 
increments of 5 BMI units were used to allow backtranslation to approximate WHO categories. This 
allows for international comparison with other published research on maternal BMI, and facilitates 
interpretation for clinical practice, public health and policymaker decisions which have a tendency to 
utilise BMI categories.  
 
A further strength of this systematic review is the rigorous search strategy. It has been demonstrated 
that database searches alone are not sufficient for epidemiology systematic reviews25, and the Meta
analysis Of Observational Studies in Epidemiology (MOOSE) guidelines73 recommend that additional 
searches may be necessary. We performed rigorous database searches including pilot and refinement 
of the search strategy by the research team, including an information scientist with expertise in 
database searching. This was supplemented by additional searches in our six stage search strategy to 
identify the full evidencebase. Among the studies identified using additional search methods, some 
were published in journals not indexed on the bibliographic databases and therefore would not have 
been identified by database searches alone. Furthermore, the postterm data presented in a number of 
studies was not a primary outcome, rather one outcome among multiple adverse pregnancy outcomes 
being investigated. These studies did not include the postterm search terms in the keywords, titles or 
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abstracts and therefore would not have been identified by any search strategy using these terms. This 
rigorous search strategy was timeconsuming, although resulted in an absence of publication bias. The 
method of searching (i.e. database, reference list or citation searches) was an apriori factor considered 
in the subgroup metaanalysis and metaregression to explore sources of heterogeneity between 
studies. While the method of searching did not impact on overall heterogeneity, the subgroup analyses 
suggests that the inclusion of studies identified through database searches were more likely to show 
statistically significant results in metaanalysis than the studies identified by the additional searches 
(see table S10 for example of analysis on postterm ≥42 weeks). This result could have been due to 
more studies being included in the ≥42 weeks subgroup metaanalysis identified by database 
searches (n=12) compared with citation searches (n=4) or reference list searches (n=3). However, it 
could also suggest that database searches alone would result in positive publication bias by only 
identifying those studies more likely to show statistical significance. This result supports the MOOSE 
guidelines recommendation for supplementing database searches when carrying out systematic 
reviews of observational studies.     
 
A limitation of systematic review methodology is reliance on the availability of published data which can 
impact on the analyses. The use of selfreported last menstrual period or measured ultrasound scan is 
an important clinical factor influencing the assessment of gestational age, yet five studies did not 
specify methods of assessment for the ≥42 weeks metaanalysis, and a further seven for ≥41 weeks. 
Metaregression identified some factors considered to be important a priori which did not impact on the 
results, such as the use of selfreport or measured BMI. The use of selfreported BMI among obese 
BMI groups is a frequent methodological criticism74, yet had little influence in our metaregression 
analyses. Others have reported that the error caused by selfreport misclassification of BMI among 
overweight and obese women has minimal influence on the doseresponse analyses for large for 
gestational age, gestational diabetes and preeclampsia75. Therefore, the potential underreporting of 
selfreported BMI appears to have little influence on largescale epidemiological analysis of maternal 
weight status and pregnancy outcomes. Additionally, 25 of the included studies did not report ethnicity 
of their population and therefore we could not explore this in the metaregression or subgroup analysis 
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and makes the generalisability across ethnicities challenging. However, one quarter of the studies were 
from the Middle East, Asia or South Africa which suggests that there was some ethnic diversity present 
in the populations rather than data originating from mainly White populations. Of the studies that 
reported ethnicity, eight studies described their population as mainly White, one as all Asian, one as 
mainly African, and four described a mix of ethnic groups in the population. The metaregression did 
explore country of study and this did not impact on overall heterogeneity of results.   
       
Maternal obesity is increasing internationally, and the daily challenges for clinical and public health 
practice will also continue to increase. Results of this systematic review and metaanalyses add to the 
evidencebase of increased risks associated with maternal obesity, and can be used to inform 
preconception and pregnancy care. Policy makers should emphasise the importance of supporting 
women to reduce their BMI preconception and interpregnancy to prevent the adverse outcomes 
associated with postterm birth, such as perinatal and infant mortality. The increasing doseresponse 
association also informs healthcare planning and commissioning of services, as the level and intensity 
of intervention required to prevent adverse outcomes associated with postterm birth will differ 
according to BMI class. The data can also be used to inform the need for interventions such as 
induction of labour and caesarean delivery to prevent pregnancies progressing to postterm. These 
procedures in obese populations also present clinical challenges and require increased planning, 
evidencebased risk communication and shared decision making about birth plans. Any steps taken to 
support the health and wellbeing of women and their babies in relation to postterm birth and 
associated risks should be informed by the doseresponse association between the obesity classes. 
Further research which utilises maternal BMI should also consider the heterogeneity within obesity 
populations, and the need for adequately powered studies to explore pregnancy outcomes in the 
higher, less prevalent, obesity classes.  
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  
Maternal obesity is having a significant impact on daily clinical practice. The association between 
maternal BMI and postterm birth increases with increasing BMI, with the greatest odds among women 
in obesity class III and with postterm birth ≥42 weeks. Pregnancies which progress beyond 42 weeks 
have significantly increased risk of adverse outcomes, including perinatal mortality. This presents a 
double burden of disease among women with morbid obesity, which is also associated with the highest 
levels of socioeconomic disadvantage compared with other BMI categories. Future maternal obesity 
research should consider the heterogeneity between obesity classes. Healthcare policy and practice 
should ensure that necessary interventions are in place to prevent the adverse outcomes associated 
with postterm birth, considering the increased risk among the higher obesity classes.  
 
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23 
 
#	

#	$: MEDLINE database search 

#	% PRISMA flowchart of searches, screening, and inclusion and exclusion of studies 

#	! Association between maternal BMI and postterm birth ≥42 weeks: 3a) Linear odds ratio per 
5 maternal BMI units; 3b) Nonlinear doseresponse analysis.  
Legend: Linear and nonlinear doseresponse analyses for postterm birth ≥42 weeks. A) The squares 
and lines through the squares represent the studyspecific ORs and 95% CIs. The dimension of the 
square is proportional to the weight of the study in the metaanalysis. The diamond represents the 
summary OR.   

#	& Association between maternal BMI and postterm birth ≥41 weeks: 4a) Linear odds ratio per 
5 maternal BMI units; 4b) Nonlinear doseresponse analysis.  
Legend: Linear and nonlinear doseresponse analyses for postterm birth. A) The squares and lines 
through the squares represent the studyspecific ORs and corresponding 95% CIs. The dimension of 
the square is proportional to the weight of the study in the metaanalysis. The diamond represents the 
summary OR. B) Linear model with data from all included studies; nonlinear model following sensitivity 
analysis and exclusion of Lumme et al35, see fig. S5 and table S9.  

$ Summary of included studies 
Footnote: + Reference group for BMI. * Reference group for gestational age. Abbreviations: BMI = 
body mass index; CI = confidence interval; IQR = inter quartile range; OR = odds ratio; RR = relative 
risk 

Page 27 of 106
World Obesity Journals
Obesity Reviews
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
24 
 
% Odds ratios from linear and nonlinear doseresponse analyses for maternal BMI and postterm 
birth.  
Footnote: The midpoint generally corresponds to midpoints of WHO BMI categories. Class III obese 
was divided into two subclasses (a and b) for the postterm ≥42 weeks analysis given that data was 
available. Two studies52,72 were excluded from the nonlinear analyses as BMI was categorized in two 
groups only. Abbreviations: OR=odds ratio; CI = confidence interval; BMI=body mass index; ND=no 
data available. 

! Results of the studies included in the narrative summary.  
Footnote: Abbreviations: R = reference weight group, O = obese weight group; OR=odds ratio; 
AOR=adjusted odds ratio; CI=confidence interval 
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Abenhaim et al 2007
41
, 
Canada 
04/1987  
03/1997 
>3742 * 
>42 
 
2024.9 
+ 
<19.9 
 
2529.9  
3039.9  
>40 
Not reported 1(1) 
1.07 (0.861.33) 
1.13 (0.891.45) 
0.84 (0.551.28) 
0.76 (0.193.10) 
3
AlRayyan et al 2010
42
  
Jordan 
01/1990  
12/2000 
3741 * 
>42  
 
 
<30 
+ 
≥30.0  
Not reported Not reported 2
Arora et al 2013
48
 
Thailand 
02/2011  
08/2012 
3741 * 
42  
 
 
18.524.9
+ 
<18.5  
2529.9  
≥30  
Not reported Not reported 3
Arrowsmith et al 2011
58
  
UK 
01/2004  
12/2008 
3741
+2 
* 
41
+3
 
2024.9
+ 
<19.9 
 
2529.9  
3034.9 
3539.9  
>40 
Not reported 1(1) 
0.75 (0.660.85) 
1.24 (1.141.34) 
1.52 (1.371.70) 
1.75 (1.482.07) 
2.27 (1.782.86) 
8
Basu et al 2010
61
 South 
Africa 
02/2006 
and 
09/2006 
3741 * 
>41 
18.524.9
+ 
2529.9 
3039.9 
>40 
Not reported Not reported 3
Bhattacharya 2007
63
  
UK 
19762005 3741 * 
>41 
2024.9
+
 
<19.9 
2529.9 
3034.9 
>35 
1 (1)  
0.7 (0.60.8) 
1.2 (1.11.3) 
1.4 (1.11.6) 
0.8 (0.41.7) 
1 (1)  
0.9 (0.71.1) 
0.9 (0.81.1) 
0.9 (0.71.1) 
0.8 (0.41.8) 
5
Briese et al 2011
38
  
Germany 
19982000 Not 
reported 
18.524.9 
≥30 
Not reported 
 
1 (1)  
1.45 (1.381.52) 
4
Caughey et al 2009
21
  
USA 
01/1995 
12/1999 
37<41* 
≥41 
 
37<42* 
≥42 
Not obese 
+
  
Obese (BMI 
not defined) 
Not reported 1 (1)  
1.29 (1.18, 1.40) 
 
1 (1)  
1.20 (0.99, 1.46) 
4
Cedergren 2004
49
  
Sweden 
01/1992  
12/2001 
3741
+6 
* 
≥42 
19.826
+
 
29.135 
35.140 
>40 
Not reported 1 (1)  
1.37 (1.331.41) 
1.49 (1.401.58) 
1.80 (1.622.01) 
5
Denison et al 2008
39
  
Sweden  
19982002 3741
+6 
* 
≥42 
2025
+
 
<20 
25<30 
30<35 
≥35 
Term median BMI 
22.9 (IQR 21.0–
25.3)  
Postdate median 
BMI 23.4 (IQR 
21.5–26.0)  
p<0.0001 
Not reported 5
ElGilany and Hammad 
2010
50
 
Saudi Arabia 
01/2007
12/2007 
3742 * 
>42 
 
18.524.9
+
 
<18.5 
2529.9 
≥30 
RR (95% CI) 
1 (1)  
2.3 (0.412.3) 
2.0 (0.67.1) 
3.7 (1.211.6) 
Not reported 3
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Halloran et al 2012
19
  
USA 
20002006 3740 * 
=41 
 
 
 
=42 
18.524.9
+
 
<18.5 
2529.9 
≥30 
 
18.524.9
+
 
<18.5 
2529.9 
≥30 
Not reported Not reported 5
Johnson et al 1992
51
 
USA  
01/1987
12/1989 
3842 * 
>42 
<19.8
+
 
19.826 
2729 
>29 
1 (1)  
1.22 (0.891.66) 
1.58  (1.032.4) 
1.49 (1.012.2) 
Not reported 
 
5
Khashan and Kenny 2009
20
 
UK 
01/2004
12/2006 
Not 
reported* 
≥41 
18.524.9
+
 
<18.5 
2529.9  
3040 
>40 
1 (1) 
0.79 (0.650.96) 
1.13 (1.061.21) 
1.28 (1.191.38) 
1.17 (0.951.43) 
1 (1) 
0.81 (0.670.99) 
1.17 (1.091.25) 
1.35 (1.251.45) 
1.24 (1.021.52) 
5
Kistka et al 2007
40
  
USA 
19891997 3741+6 * 
≥42 
 
Reference not 
defined
+
 
<20 
>35 
1 (1) 
0.90 (0.880.93) 
1.25 (1.191.32) 
1 (1) 
0.85 (0.820.87) 
1.23 (1.161.29) 
4
Kitiyodom and 
Tongswatwong 2008
67
  
Thailand 
10/2004
09/2006 
Reference 
not defined
+
 
Postterm 
not defined 
2024.9
+ 
>25 
1 (1) 
1.7 (1.192.44) 
 
Not reported 3
Knight et al 2010
68
  
UK 
09/2007
08/2008 
Reference 
not defined 
+
 
>42 
 
<50
+
 
≥50 
1 (1) 
1.31 (0.762.25) 
1 (1) 
1.35 (0.772.37) 
4
Konje et al 1993
72
 
UK 
01/1989
06/1990 
3742 * 
>42 
1724
+ 
30.453.0 
Not reported Not reported 4
Leung et al 2008
34
  
Hong Kong 
01/1995
12/2005 
3740+6 * 
≥41 
18.5<23
+
 
<18.5 
≥23<25 
≥25<27.5 
≥27.5<30 
≥30 
Not reported 1 (1) 
0.84 (0.740.95) 
1.06 (0.971.17) 
1.21 (1.081.36) 
1.25 (1.051.48) 
1.34 (1.091.66) 
 
4
Lumme et al 1995
35
 
Finland 
07/1985
06/1986 
3741 * 
>41 
1924.9
+
 
<19 
2529.9 
≥30 
Not reported 1 (1) 
1.0 (0.71.4) 
1.6 (1.22.1) 
1.1 (0.61.9) 
4
Mancuso et al 1991
36
  
Italy 
Not 
reported 
3841 *  
>42 
15.226.6
+
 
>30 
Not reported Not reported 1
Manzanares et al 2012
37
  
Spain 
20072009 3741
+2  
* 
>41
+3
 
18.525
+
 
<18.5 
>35 
Not reported 1 (1) 
0.81 (0.351.91) 
0.72 (0.341.55) 
4
Morgan et al 2014
43
 
UK 
11/2010
02/2013 
Reference 
not defined 
+ 
=42 
18.524.9
+
 
2529.9 
>29.9 
1 (1) 
 
2.18 (0.994.84) 
Not reported 4
Navid et al 2013
69
 
Pakistan 
05/2011 
07/2012 
3740* 
>40 
1824.9
+
 
2535 
Not reported Not reported 2
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Nohr et al 2009
70
 
Denmark 
19962002 3741* 
>41 
1533.3
+
 
32.6<35 
35<37.5 
≥37.5 
Not reported 1 (1) 
1.3 (1.11.5) 
1.5 (1.31.8) 
1.4 (1.21.7) 
4
Olesen et al 2006
65
  
Denmark 
19962004 37 41
+6  
* 
≥42 
2024
+
 
<20 
2529 
3034 
≥35 
1  
0.87  
1.23  
1.35  
1.48 
95%CI not 
reported 
1 (1) 
0.87 (0.800.94) 
1.24 (1.151.34) 
1.37 (1.221.54) 
1.52 (1.281.82) 
3
Raatikainen et al 2006
53
  
Finland 
01/1989 
12/2001 
Reference 
not defined 
+   
>42 
≤25
+
 
2629 
≥30 
Not reported Not reported 5
Robinson  et al 2005
37
  
Canada 
01/1988 
12/1992 
Reference 
not defined 
+ 
>41  
5575Kg
+
 
≥90120Kg 
>120Kg 
1 (1) 
1.10 (1.011.20) 
0.91 (0.671.23) 
1 (1) 
1.18 (1.081.28) 
0.99 (0.741.34) 
4
Rode et al 2005
54
 
Denmark 
1998  
2001 
3742*  
>42 
<25
+ 
2529.9 
≥30 
Not reported 1 (1) 
1.4 (1.21.7) 
1.4 (1.11.9) 
5
Roos et al 2010
55
 
Sweden 
01/1992 
12/2006 
3741+6* 
≥42 
2024.9
+
 
<20 
2529.9 
≥30 
Not reported 1 (1) 
0.74 (0.720.76) 
1.31 (1.291.33) 
1.63 (1.591.67) 
8
Schrauwers and Dekker 
2009
62
 
Australia 
01/2006 
06/2006 
3741* 
>41 
19.125
+
 
25.130 
30.140 
>40 
Not reported Not reported 2
ScottPillai et al 2013
59
 
UK 
20042011 Reference 
not defined 
+ 
>41 
18.524.99
+
 
<18.50 
2529.99 
3034.99 
3539.99 
≥40 
Not reported 1 (1) 
0.5 (0.21.0) 
0.9 (0.71.1) 
0.8 (0.51.1) 
0.9 (0.51.6) 
0.8 (0.41.7) 
7
Sharief and Tarik 2000
36
 
Iraq 
12/1997
08/1998 
Reference 
not defined 
+ 
Postterm 
not defined 
<=90Kg 
>90Kg 
Not reported Not reported 3
Stotland et al 2007
56
 
USA 
19902001 37<41* 
≥41 
 
 
 
37<42* 
≥42 
19.826
+
 
<19.8 
26.129 
>29 
Not reported 1 (1) 
0.83 (0.720.95) 
1.29 (1.101.52) 
1.81 (1.502.18) 
 
1 (1) 
0.78 (0.601.01) 
1.51 (1.151.97) 
1.69 (1.232.31) 
6
Usha Kiran et al 2005
44
 
UK  
19901999 3741*  
>41 
2030
+
 
>30 
1 (1) 
1.4 (1.21.7) 
Not reported 4
Vaswani and Balachandran 
2013
60
 
United Arab Emirates 
12/2010 
10/2011 
3741* 
>41 
18.524.9
+
 
2529.9 
3034.9 
3539.9 
≥40 
Not reported 1 (1) 
1.54 (0.892.65) 
1.69 (0.962.98) 
1.78 (0.933.42) 
2.99 (1.356.65) 
4
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Vinturache et al 2014
57
 
Canada 
05/2008 
12/2010 
3741
+6 
* 
≥42 
18.524.99
+
 
2529.99 
≥30 
Not reported Not reported 5
Voigt et al 2008
71
 
Germany 
19982000 Term, not 
defined 
+
 
Postterm, 
not defined 
18.524.99
+
 
4044.99 
≥45 
Not reported Not reported 2
Yazdani et al 2006
66
 
Iran 
20082009 Term, not 
defined 
+
 
Postterm, 
not defined 
2024.9
+
 
≤19.9 
2529.9 
3034.9 
>35 
Not reported Not reported 2
Footnote: 
+
 Reference group for BMI. * Reference group for gestational age. Abbreviations: BMI = 
body mass index; CI = confidence interval; IQR = inter quartile range; OR = odds ratio; RR = relative 
risk 
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
Figure 3: Association between maternal BMI and postterm birth ≥42 weeks: 3a) Linear odds ratio per 5 
maternal BMI units  
Legend: Linear doseresponse analyses for postterm birth ≥42 weeks. A) The squares and lines through the 
squares represent the studyspecific ORs and 95% CIs. The dimension of the square is proportional to the 
weight of the study in the metaanalysis. The diamond represents the summary OR.  
fig. 3a  
1098x714mm (96 x 96 DPI)  
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Figure 3: Association between maternal BMI and postterm birth ≥42 weeks: 3b) Nonlinear doseresponse 
analysis.  
Legend: Nonlinear doseresponse analyses for postterm birth ≥42 weeks.  
fig. 3b  
1893x1192mm (96 x 96 DPI)  
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Figure 4: Association between maternal BMI and postterm birth ≥41 weeks: 4a) Linear odds ratio per 5 
maternal BMI units.  
Legend: Linear doseresponse analyses for postterm birth. A) The squares and lines through the squares 
represent the studyspecific ORs and corresponding 95% CIs. The dimension of the square is proportional to 
the weight of the study in the metaanalysis. The diamond represents the summary OR.  
fig. 4a  
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Figure 4: Association between maternal BMI and postterm birth ≥41 weeks: 4b) Nonlinear doseresponse 
analysis.  
Legend: Nonlinear doseresponse analyses for postterm birth. B) Linear model with data from all included 
studies; nonlinear model following sensitivity analysis and exclusion of Lumme et al35, see fig. S5 and table 
S9.  
fig. 4b  
1018x714mm (96 x 96 DPI)  
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Table 2: Odds ratios from linear and nonlinear doseresponse analyses for 
maternal BMI and postterm birth 
  BMI Class (Midpoint BMI, kg/m
2
) 
 Model Underweight 
(17.5) 
Reference 
BMI (22.5) 
Overweight 
(27.5) 
Obese I 
(32.5) 
Obese II 
(37.5) 
Obese IIIa 
(42.5) 
Obese IIIb 
(47.5) 
P
o
s
t
te
rm
 ≥
4
2
 
w
e
e
k
s
 
Linear 
OR (95% CI) 
0.84 
(0.76,0.94) 
1 
1.19 
(1.12,1.27) 
1.38 
(1.31,1.46) 
1.57 
(1.50,1.64) 
1.76 
(1.69,1.83) 
1.95 
(1.88,2.02) 
Nonlinear 
OR (95% CI) 
0.81 
(0.74,0.88) 
1 
1.24 
(1.15,1.34) 
1.42 
(1.27,1.58) 
1.55 
(1.37,1.75) 
1.65 
(1.44,1.87) 
1.75 
(1.50,2.04) 
P
o
s
t
te
rm
 ≥
4
1
 
w
e
e
k
s
 
Linear 
OR (95% CI) 
0.88 
(0.83,0.95) 
1 
1.13 
(1.05,1.21) 
1.26 
(1.18,1.34) 
1.39 
(1.31,1.47) 
1.52 
(1.44,1.54) 
ND 
Nonlinear 
OR (95% CI) 
0.91 
(0.85,0.97) 
1 
1.11 
(1.04,1.20) 
1.22 
(1.07,1.39) 
1.33 
(1.10,1.59) 
1.44 
(1.13,1.83) 
ND 
Footnote: The midpoint generally corresponds to midpoints of WHO BMI categories. Class III obese was divided into two sub"
classes ( and ) for the post"term ≥42 weeks analysis given that data was available. Two studies
52,72
 were excluded from the 
nonlinear analyses as BMI was categorized in two groups only. Abbreviations: OR=odds ratio; CI = confidence interval; 
BMI=body mass index; ND=no data available. 
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Abenhaim 
et al 2007
41
 
Canada 18,633 R: BMI 20 to 24.9 
O1: BMI 30 to 39.9  
O2: BMI >40  
>42 weeks O1: AOR 0.84 (95% CI 0.55'1.28) 
O2: AOR 0.76 (95% CI 0.19'3.10) 
Frequency data not provided 
No significant 
difference 
No frequency data 
provided 
Al'Rayyan 
et al 2010
42
 
Jordan 1,008 R: BMI <30 
O: BMI >30 
>42 weeks R: n=55, 10.6% 
O: n=54, 11.0% 
Statistical analysis not reported 
No difference Non'comparable 
BMI reference 
group 
Briese et al 
2011
38
 
Germany 243,571 R: BMI 18.5 to 24.9 
O: BMI >30 
Not 
defined 
AOR 1.45 (95% CI 1.38'1.52) 
Frequency data not provided 
Significantly 
increased 
No frequency data 
provided 
Caughey et 
al 2009
21
 
USA 119,162 R: ‘Not obese’ 
O: ‘Obese’ 
Not defined 
>41 weeks 
>42 weeks 
>41 weeks AOR 1.26 (95% CI 1.16'1.37) 
>42 weeks AOR 1.20 (95% CI 0.99'1.46) 
Frequency data not provided 
Significantly 
increased (41 
weeks only) 
No frequency data 
provided; Non'
comparable BMI 
reference group 
Denison et 
al 2008
39
 
Sweden 143,519 R: BMI 20 to <25 
O1: BMI 30 to <35  
O2: BMI >35  
>294 days 
(42 weeks) 
Higher maternal BMI in 1
st
 trimester 
increased post'term (p<0.001) 
Significantly 
increased 
No frequency data 
provided 
Kistka et al 
2007
40
 
USA 368,633 R: not defined 
O:BMI >35 
>42 weeks AOR 1.23 (95% CI 1.16'1.29) 
Frequency data not provided 
Significantly 
increased 
No frequency data 
provided 
Mancuso et 
al 1991
36
 
Italy 160 R: BMI 15.2'26.6 
O: BMI >30 
>42 weeks R: n=1 
O: n=3 
p >0.05 
No significant 
difference 
Non'comparable 
BMI reference 
group 
Robinson 
et al 2005
37
 
Canada 142,404 R: 55 to 75kg 
O1: 90 to 120kg 
O2: >120kg  
>41 weeks R: n=4997, 6.3% 
O1: n=647, 6.9%;  AOR 1.18 (95% CI 
1.08'1.28) 
O2: n=45, 5.8%; AOR 0.99 (95% CI 0.74'
1.34) 
Significantly 
increased (O1 
only) 
Maternal exposure 
weight 
Sharief et 
al 2000
36
 
Iraq 40 R: ≤90kg 
O: >90kg 
Not 
defined 
R: n=3, 15% 
O: n=3, 15% 
Statistical analysis not reported 
No difference Maternal exposure 
weight  
Usha Kiran 
et al 2005
44
 
Wales 8,350 R: BMI 20 to 30 
O: BMI >30 
>41 weeks R: n=2490, 32.5% 
O: n=278, 41.0%; OR 1.4 (95% CI 1.2'
1.7) 
Significantly 
increased 
Non'comparable 
BMI reference 
group 
Footnote: Abbreviations: R = reference weight group, O = obese weight group; OR=odds ratio; AOR=adjusted odds ratio; CI=confidence interval 
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Figure S1: Translation of search terms across databases 
 
Embase (OVID) 1974 to 2015 Week 21 
1. *Pregnancy/ 
2. Pregnan$. ti,ab. 
3. Matern$. ti,ab. 
4. Obes$. ti,ab. 
5. (Body adj1 composition). ti,ab. 
6. (BMI or Body mass index).ti,ab. 
7. Weight.ti,ab. 
8. (Post adj1 term$).mp.  
9. Postterm$.mp. 
10. (Post adj1 date$).mp. 
11. Postdate$.mp.  
12. (Prolonged adj1 pregnanc$).mp.  
13. (Fetomaternal adj1 morbidity).mp. 
14. Gestation.mp. 
15. Postmaturity.mp. 
16. (Post adj1 maturity).mp. 
17. Cohort studies/ or longitudinal studies/ or followup studies/ or prospective studies/ or 
retrospective studies/ or cohort.ti,ab. or longitudinal.ti,ab. or prospective.ti,ab. or 
retrospective.ti,ab.  
18. CaseControl Studies/ or Control Groups/ or MatchedPair Analysis/ or ((case* adj5 control*) or 
(case adj3 comparison*) or control group*).ti,ab.  
19. CrossSectional Studies/ or crosssectional.ti,ab. or ("prevalence study" or "incidence study" or 
"prevalence studies" or "incidence studies" or "transversal studies" or "transversal study").ti,ab.  
20. 1 or 2 or 3 
21. 4 or 5 or 6 or 7 
22. 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 
23. 17 or 18 or 19 
24. 20 and 21 and 22 and 23 
25. Limit 24 to human 
26. Limit 25 to female 
27. *Body Mass Index/ 
28. exp Overweight/ 
29. *Obesity/ or *Obesity, Morbid/ 
30. 21 or 27 or 28 or 29 
31. *prolonged pregnancy/ 
32. *pregnancy outcome/ 
33. *pregnancy complication/ 
34. 22 or 31 or 32 or 33 
35. 20 and 23 and 30 and 34 
36. 35 not 24 
37. Limit 36 to human 
38. Limit 37 to female 
Note: .mp.=title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer, device trade name, keyword 
 
 
PsycINFO (OVID) 1806 to May Week 3 2015 
1. *Pregnancy/ 
2. Pregnan$. ti,ab. 
3. Matern$. ti,ab. 
4. Obes$. ti,ab. 
5. (Body adj1 composition). ti,ab. 
6. (BMI or Body mass index).ti,ab. 
7. Weight.ti,ab. 
8. (Post adj1 term$).mp.  
9. Postterm$.mp. 
10. (Post adj1 date$).mp. 
11. Postdate$.mp.  
12. (Prolonged adj1 pregnanc$).mp.  
13. (Fetomaternal adj1 morbidity).mp. 
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14. Gestation.mp. 
15. Postmaturity.mp. 
16. (Post adj1 maturity).mp. 
17. Cohort studies/ or longitudinal studies/ or followup studies/ or prospective studies/ or 
retrospective studies/ or cohort.ti,ab. or longitudinal.ti,ab. or prospective.ti,ab. or 
retrospective.ti,ab.  
18. CaseControl Studies/ or Control Groups/ or MatchedPair Analysis/ or ((case* adj5 control*) or 
(case adj3 comparison*) or control group*).ti,ab.  
19. CrossSectional Studies/ or crosssectional.ti,ab. or ("prevalence study" or "incidence study" or 
"prevalence studies" or "incidence studies" or "transversal studies" or "transversal study").ti,ab.  
20. 1 or 2 or 3 
21. 4 or 5 or 6 or 7 
22. 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 
23. 17 or 18 or 19 
24. 20 and 21 and 22 and 23 
25. Limit 24 to human 
26. Limit 25 to female 
27. *Body Mass Index/ 
28. Exp Overweight/ 
29. *Obesity/ or *Obesity, Morbid/ 
30. 21 or 27 or 28 or 29 
31. *obstetrical complications/ 
32. *pregnancy outcomes/ 
33. 22 or 31 or 32 
34. 20 and 23 and 30 and 33 
35. 34 not 24 
36. Limit 36 to human 
37. Limit 37 to female 
Note:.mp.=title, abstract, heading word, table of contents, key concepts, original title, tests and measures 
 
 
CINAHL (EBSCO) 19814May 2015 
1 MM pregnancy OR TI pregnan* OR TI matern* OR AB pregnan* OR AB matern* 
2 MM body mass index OR MM obesity OR MH overweight+ OR TI obes* OR AB obes* OR TI 
body w1 composition OR AB body w1 composition  OR TI bmi OR AB bmi OR TI body mass 
index OR AB body mass index  
3 TI weight OR AB weight 
4 2 OR 3 
5 TX ( post term* or postterm* ) OR TX ( (post w1 date*) or postdate* ) OR TX prolonged w1 
pregnanc* OR TX fetomaternal w1 morbidity OR TX gestation OR TX postmaturity OR TX post 
w1 maturity OR MM “infant, postmature” OR MM “pregnancy outcomes” OR MM “pregnancy 
complications” 
6 (MH “prospective studies”) OR (MH “case control studies+”) OR (MH “correlational studies”) OR 
(MH “nonconcurrent prospective studies”) OR (MH “cross sectional studies”) 
7 TX (cohort w1 (study or studies)) 
8 TX (observational w1 (study or studies)) 
9 6 OR 7 OR 8 
10 1 AND 4 AND 5 AND 9 
 
 
British Nursing Index (NHS HDAS) 19924May 2015 
1. (pregnan* OR matern*).ti,ab. 
2. PREGNANCY/ 
3. 1 or 2 
4. (obes* OR (body adj1 composition) OR bmi OR (body mass index) OR weight).ti,ab. 
5. OBESITY/ 
6. 4 OR 5 
7. (postterm* OR (post adj1 term) OR postdate* OR (post adj1 date*) OR (prolonged adj1 
pregnan*) OR (fetomaternal adj1 morbidity) OR gestation OR postmaturity OR (post adj 
maturity)).af 
8. PREGNANCY : COMPLICATIONS/ 
9. 7 OR 8 
10. 3 AND 6 AND 9 
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Table S1: Data extraction protocol   
 
 
 
 
 




















 
 






















       



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Figure S2: Adapted Newcastle4Ottatwa Scale 1 for Cohort Studies# 
Selection 
1) Representativeness of the exposed cohort (exposure in this context is maternal BMI risk group, 
e.g. obesity) 
a) truly representative of the average pregnant population in the community * 
b) somewhat representative of the average pregnant population in the community * 
c) selected group of users (eg only first time pregnancy, only teenage pregnancy etc) 
d) no description of the derivation of the cohort  
2) Selection of the non exposed cohort (nonexposure is the maternal BMI group used as reference 
e.g. recommended BMI) 
a) drawn from the same community as the exposed cohort* 
b) drawn from a different source (E.g. different maternity unit, different specialist clinic, different 
time range for recruitment between BMI groups) 
c) no description of the derivation of the non exposed cohort   
3) Ascertainment of exposure (maternal weight status) 
a) secure record * (Measured weight used)  
b) validated selfreport * (selfreport with measured weight validation) 
c) self report   
d) no description  
4) Demonstration that outcome of interest was not present at start of study ## 
a) yes * 
b) no 
Comparability 
4) Comparability of cohorts on the basis of the design or analysis 
a) study controls for induction of labour or caesarean * (either excluded or adjusted) 
b) study controls for any additional factor * 
c) no factors controlled for  
Outcome 
5) Assessment of outcome (outcome is gestational age at delivery)  
a) independent blind assessment/measured * (e.g. measurement (ultrasound scan) carried out 
prospectively for research purposes)   
b) record linkage/measured * (e.g. retrospective routine hospital records of ultrasound scan to 
confirm gestational age) 
c) self report (e.g. last menstrual period)  
d) no description  
6) Was followup long enough for outcomes to occur (until spontaneous onset of labour before 
postterm definition)  
a) yes * 
b) no  
7) Adequacy of follow up of cohorts 
a) complete follow up  all subjects accounted for * 
b) subjects lost to follow up unlikely to introduce bias  small number lost to follow up >80 % 
(select an adequate %), or description provided of those lost *  
c) follow up rate < 80% and no description of those lost  
d) no statement  
Total number of stars (out of a possible 8
###
): 
Notes:  
# There were no true case control studies included in the systematic review where the case and control 
status was defined based on the case definition of the outcome variable (i.e. gestational age at delivery). 
Those studies which had been described by authors as case control, or that followed a case control method 
of selecting “cases” and “controls” (n=4) used the exposure status (BMI) to allocate case or control status. 
Therefore these studies used the pre/early pregnancy baseline exposure status to define the groups and 
followed the women for the duration of their pregnancy until birth to ascertain delivery outcomes (either 
prospectively or retrospectively). These study designs better fit the cohort design Quality Assessment Scale 
and therefore this has been used for all included studies.  
 
## Question 4 “Demonstration that outcome of interest was not present at start of study” is not applicable to 
gestational age at delivery outcomes as women are identified in early pregnancy using their pre/early 
pregnancy BMI and their pregnancy outcomes are not known at the start of the study. Therefore this item 
has been removed from the scale  
 
### The denominator value for the maximum number of stars a study can be awarded has been reduced 
from 9 to 8 due to the removal of the original question 4.  
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Table S2: Screening: systematic review reference lists screened, and full papers 
screened and excluded 
 
Table S2a: Reference lists of systematic reviews screened 
Review Number of references screened 
Bogaerts et al 2013 2 70 
Castro and Avina 2002 3 31 
Catalano and Ehrenberg 2006 4  55 
Caughey et al 2008 5  99 
Gülmezoglu et al 2012 6 137 
Heslehurst et al 2008 7  85 
Linne 2004 8 93 
Lutsiv et al 2015 9 94 
McDonald et al 2010  10  102 
Nuthulapaty and Rouse 2004 11  97 
Torloni et al 2009 12   77 
Vasudevan et al 2011 13 50 
Walker and Gan 2015 14 8 
Wolfe 1998 15 10 
 
Table S2b: Full details of studies excluded following full paper review 
References of studies screened in full and excluded 
 
Exclusion Reason Reference Number 
Abstract/poster only 118 
	




BMI at term/late pregnancy 1922 
BMI not an exposure 2332 
Multiple gestations only 33 
Not post term 34142 
Not primary research 143159 
Restricted subsample of maternity population 160169 
Unpublished student dissertation 170 
Reference list of excluded studies 
1. Cidade, D. G., P. R. Margotto, A. C. B. S. Guedes, A. A. Rocha, F. R. Assis, F. F. Cardoso, R. C. R. 
Lemes, V. T. M. Borges and J. C. Peracoli (2012). "High prevalence of prepregnancy overweight and 
obesity associated with maternal and perinatal complications." Pregnancy Hypertension 2 (3): 323. 
2. Darsareh, F. and S. Nourbakhsh (2012). "Prepregnancy body mass index and the risk of prolonged 
pregnancy." International Journal of Gynecology and Obstetrics 119: S756. 
3. Guariglia, L., P. Ciliberti, S. Buongiorno, A. Alessio, E. Nobili, M. Tintoni, P. Rosati and G. Capelli 
(2013). "Risk factors in prolonged pregnancy." Journal of Perinatal Medicine 41. 
4. Hallaron, D. R., N. Marshall, Y. W. Cheng and A. B. Caughey (2012). "Effect of obesity on induction 
across gestational age." American Journal of Obstetrics and Gynecology 1): S250. 
5. Idris, N. and K. N. C. Nyan (2012). "The association of maternal obesity and gestational weight gain 
with obstetric and neonatal outcomes among parturients in Seremban, Malaysia." BJOG: An 
International Journal of Obstetrics and Gynaecology 119: 75. 
6. Kapoor, D. and S. Rajendran (2013). "Can we improve care and outcomes of pregnancy in women with 
morbid obesity?" BJOG: An International Journal of Obstetrics and Gynaecology 120: 3031. 
7. Kapoor, D., J. Davison and S. Rajendran (2013). "Audit on care and outcome of pregnancy in women 
with morbid obesity." Archives of Disease in Childhood: Fetal and Neonatal Edition 98. 
8. Lam, S., L. Kindinger and L. Phelan (2012). "Weight gain in pregnancy." Archives of Disease in 
Childhood: Fetal and Neonatal Edition 97: A114. 
9. Marshall, N. E., C. Guild, Y. W. Cheng, A. B. Caughey and D. R. Halloran (2012). "Impact of maternal 
BMI on induction of labor." American Journal of Obstetrics and Gynecology 1): S147. 
10. Marshall, N. E., J. M. Snowden, P. F. O'TierneyGinn, K. Melsap, J. Chung, E. Main, W. Gilbert and A. 
B. Caughey (2013). "Influence of fetal sex, maternal obesity, and gestational weight gain on perinatal 
outcomes." Reproductive Sciences 1): 309A310A. 
11. Martin, K., R. M. Grivell, L. N. Yelland and J. M. Dodd (2013). "Gestational diabetes mellitus among 
women who are overweight and obese: The effect of BMI category." Obesity Research and Clinical 
Practice 7: 11. 
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References of studies screened in full and excluded 
 
12. Nohr, E. A. (2012). "Obesity in pregnancy. Outcomes in the mother and child." Obesity Facts 5: 20. 
13. O'Dwyer, V., J. Hogan, N. Farah, M. M. Kennelly, B. Stuart and M. J. Turner (2012). "Changes in 
maternal body composition during pregnancy." Archives of Disease in Childhood: Fetal and Neonatal 
Edition 97: A47. 
14. Oniya, O., K. Hanretty, J. Gibson and K. Guerrero (2010). "Audit of pregnancy outcomes and co
morbidities in the obese population." Obesity Reviews 11 (11): 830. 
15. Redfearn, C. F., S. Wandiembe and E. OtengNtim (2012). "Quantification of healthcare costs of 
obesity in pregnancy: A retrospective observational cohort study." Archives of Disease in Childhood: 
Fetal and Neonatal Edition 97: A110. 
16. Schuster, M. Neubert, A. Kirchner, L Paglia, M. The impact of body mass index on pregnancy 
complications. 2015. American Journal of Obstetrics and Gynaecology. 1): S421. 
17. Suresh, A., A. Liu, A. Poulton, A. Quinton, Z. Amer, M. Mongelli, A. Martin, R. Benzie, M. Peek and R. 
Nanan (2012). "Comparison of maternal abdominal subcutaneous fat thickness and body mass index 
as markers for pregnancy outcomes: A stratified cohort study." Australian and New Zealand Journal 
of Obstetrics and Gynaecology 52(5): 420426. 
18. Trombe, K. S. D., H. Bettiol, R. C. Cavalli, M. R. P. Gutierrez, M. A. Barbieri, C. Grandi and V. C. 
Cardoso (2014). "Association between maternal prepregnancy body mass index and size at birth in 
Ribeirao Preto, Sao Paulo, Brazil." Archives of Disease in Childhood 99: A240. 
19. Fatima, S. A. Rehman, S. A. Gangat, A. Kamal, Z. Ahmad (2011). “To compare maternal and fetal 
outcome in obese verses nonobese labouring mothers.” Journal University Medical and Dental 
College 2(2): JulDec 2011. 
20. Mamula, O., N. S. Severinski, M. Mamula and S. Severinski (2009). "Complications during pregnancy, 
labor and puerperium in women with increased BMI at pregnancy term." Central European Journal of 
Medicine 4(1): 7175. 
21. Metzger, B. E. (2010). "Hyperglycaemia and adverse pregnancy outcome (HAPO) study: Associations 
with maternal body mass index." BJOG: An International Journal of Obstetrics and Gynaecology 
117(5): 575584. 
22. Pongthai, S. (1990). "Labour and delivery of obese parturients." Journal of the Medical Association of 
Thailand 73 Suppl 1: 5256. 
23. Campbell MK, Ostbye T, Irgens LM. Postterm birth: risk factors and outcomes in a 10year cohort of 
Norwegian births. Obstet Gynecol1997;89:5438. 
24. Caughey and Bishop, Maternal complications of pregnancy increase beyond 40 weeks of gestation in 
lowrisk women. J Perinatol 2006:26:540545 
25. Caughey et al Maternal and obstetric complications of pregnancy are associated with increasing 
gestational age at term. Am j obstet gynecol 2007 196(2)155 e16 
26. Collins, J. W., N. F. Schulte, L. George and A. Drolet (2000). "Postterm delivery among African 
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Table S3: Details of included studies as reported in the original papers 
Author, 
publication 
year, region, 
country  
 
Methodology Number of 
participants: 
number of 
cases
1
 
Study 
period 
 
Assessment 
of weight 
status 
Assessment 
of gestational 
age 
Gestational 
age groups 
(weeks) 
BMI (kg/m
2
)  
or weight 
category 
Participants 
per BMI 
category 
Cases per 
BMI 
category 
Crude analysis 
(OR and 95% CI 
unless otherwise 
specified) 
Adjusted analysis 
(OR and 95% CI 
unless otherwise 
specified) 
Variables included in 
adjusted analyses 
Abenhaim et al 
200716  
Canada 
Retrospective 
Cohort 
18,633:not 
reported 
 
04/1987 
03/1997 
Prepregnancy 
BMI, method 
of assessment 
not reported# 
Not reported >3742 * 
>42 
 
2024.9 + 
<19.9  
2529.9  
3039.9  
>40 
10,015 
4,310 
3,067 
1,137 
104 
Not reported Not reported 1(1) 
1.07 (0.861.33) 
1.13 (0.891.45) 
0.84 (0.551.28) 
0.76 (0.193.10) 
Maternal Age 
Parity 
Smoking 
Preexisting diabetes 
AlRayyan et al 
201017  
Jordan 
Retrospective 
Cohort 
 
 
901:109 01/1990  
12/2000 
Early 
pregnancy 
measured BMI  
Not reported 3741 * 
>42  
 
 
<30 + 
≥30.0  
461 
440 
55 
54 
Not reported Not reported N/A 
Arora et al 
201318 
Thailand 
Retrospective 
Cohort 
4,764:32 02/2011  
08/2012 
Prepregnancy 
BMI, method 
of assessment 
not reported#  
Not reported 3741 * 
42  
 
 
18.524.9+ 
<18.5  
2529.9  
≥30  
3,129 
912 
535 
188 
19 
7 
5 
1 
Not reported Not reported N/A 
Arrowsmith et al 
201119  
UK 
Retrospective 
Cohort 
20,599:Not 
reported 
 
 
01/2004  
12/2008 
Early 
pregnancy 
measured BMI  
USS 3741+2 * 
41+3 
2024.9+ 
<19.9  
2529.9  
3034.9 
3539.9  
>40 
Not reported Not reported 
 
Not reported 1(1) 
0.75 (0.660.85) 
1.24 (1.141.34) 
1.52 (1.371.70) 
1.75 (1.482.07) 
2.27 (1.782.86) 
Maternal age 
Race 
Parity 
Hypertension 
Diabetes mellitus 
Smoking 
Basu et al 
201020 South 
Africa 
Retrospective 
Cohort 
738:132 02/2006 and 
09/2006 
Early 
pregnancy 
measured BMI 
USS + LMP 3741 * 
>41 
18.524.9+ 
2529.9 
3039.9 
>40 
139 
273 
288 
38 
18 
54 
49 
11 
Not reported Not reported N/A 
Bhattacharya 
200721  
UK 
Retrospective 
Cohort 
21,511:1,374 19762005 Early 
pregnancy 
measured BMI  
USS + LMP 3741 * 
>41 
2024.9+ 
<19.9 
2529.9 
3034.9 
>35 
12,539 
2,497 
4,735 
1,615 
125 
773 
108 
350 
136 
7 
1 (1)  
0.7 (0.60.8) 
1.2 (1.11.3) 
1.4 (1.11.6) 
0.8 (0.41.7) 
1 (1)  
0.9 (0.71.1) 
0.9 (0.81.1) 
0.9 (0.71.1) 
0.8 (0.41.8) 
Relevant 
sociodemographic 
characteristics 
Year of delivery. 
 
Briese et al 
201122  
Germany 
Retrospective 
Cohort 
 
Not reported 19982000 BMI, method 
of assessment 
not reported 
Not reported Not reported 18.524.9 
≥30 
Not reported 
 
Not reported 
 
Not reported 
 
1 (1)  
1.45 (1.381.52) 
Age 
Smoking status 
Single mother status 
Education 
Only included 
primiparous women 
Caughey et al 
200923  
USA 
Retrospective 
Cohort 
Not reported 01/1995 
12/1999 
BMI, method 
of assessment 
not reported 
Not reported 37<41* 
≥41 
 
37<42* 
≥42 
Not obese +  
Obese (BMI 
not defined) 
Not reported Not reported Not reported 1 (1)  
1.29 (1.18, 1.40) 
 
1 (1)  
1.20 (0.99, 1.46) 
Excluding chronic 
hypertension, diabetes 
mellitus, and gestational 
diabetes mellitus. 
Controlling for paternal 
race/ethnicity. 
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Author, 
publication 
year, region, 
country  
 
Methodology Number of 
participants: 
number of 
cases
1
 
Study 
period 
 
Assessment 
of weight 
status 
Assessment 
of gestational 
age 
Gestational 
age groups 
(weeks) 
BMI (kg/m
2
)  
or weight 
category 
Participants 
per BMI 
category 
Cases per 
BMI 
category 
Crude analysis 
(OR and 95% CI 
unless otherwise 
specified) 
Adjusted analysis 
(OR and 95% CI 
unless otherwise 
specified) 
Variables included in 
adjusted analyses 
Cedergren 
200424  
Sweden 
Retrospective 
Cohort 
580,970: 
45,288 
01/1992  
12/2001 
Early 
pregnancy 
measured BMI  
USS 3741+6 * 
≥42 
19.826+ 
29.135 
35.140 
>40 
501,954 
64,286 
11,605 
3,125 
37,640 
6,072 
1,197 
379 
Not reported 1 (1)  
1.37 (1.331.41) 
1.49 (1.401.58) 
1.80 (1.622.01) 
Maternal age 
Parity 
Smoking 
Year of birth 
Denison et al 
200825  
Sweden  
Retrospective 
Cohort 
143,519:9,759 19982002 Early 
pregnancy 
measured BMI 
USS + LMP 3741+6 * 
≥42 
2025+ 
<20 
25<30 
30<35 
≥35 
84,963 
18,227 
30,139 
7,463 
2,440 
Not reported Term median BMI 
22.9 (IQR 21.0–
25.3)  
Postdate median 
BMI 23.4 (IQR 
21.5–26.0)  
p<0.0001 
Not reported N/A 
ElGilany and 
Hammad 201026 
Saudi Arabia 
Prospective 
Cohort 
787:22 01/2007
12/2007 
Early 
pregnancy 
measured BMI  
LMP 3742 * 
>42 
 
18.524.9+ 
<18.5 
2529.9 
≥30 
 
307 
67 
187 
226 
 
4 
2 
5 
11 
RR (95% CI) 
1 (1)  
2.3 (0.412.3) 
2.0 (0.67.1) 
3.7 (1.211.6) 
Not reported N/A 
 
Halloran et al 
201227  
USA 
Retrospective 
Cohort 
267,126: 
51,420 
 
 
 
267,126: 
13,392 
20002006 Selfreport pre
pregnancy BMI 
Clinical 
measurement 
3740 * 
=41 
 
 
 
=42 
18.524.9+ 
<18.5 
2529.9 
≥30 
 
18.524.9+ 
<18.5 
2529.9 
≥30 
180,056 
19,354 
76,792 
62,924 
 
180,056 
19,354 
76,792 
62,924 
26,487 
2,783 
11,794 
10,356 
 
6,866 
853 
2,997 
2,676 
Not reported Not reported N/A 
Johnson et al 
199228 
USA  
Retrospective 
Cohort 
3,203:314 01/1987
12/1989 
Selfreport pre
pregnancy BMI 
USS 3842 * 
>42 
<19.8+ 
19.826 
2729 
>29 
755 
1,633 
329 
486 
61 
157 
40 
56 
1 (1)  
1.22 (0.891.66) 
1.58  (1.032.4) 
1.49 (1.012.2) 
Not reported 
 
N/A 
Khashan and 
Kenny 200929 
UK 
Retrospective 
Cohort 
89,513:4,706 01/2004
12/2006 
Early 
pregnancy 
measured BMI 
USS + LMP Not reported* 
≥41 
18.524.9+ 
<18.5 
2529.9  
3040 
>40 
42,147 
2325 
23,757 
13,386 
1,543 
2,213 
99 
1,404 
897 
93 
1 (1) 
0.79 (0.650.96) 
1.13 (1.061.21) 
1.28 (1.191.38) 
1.17 (0.951.43) 
1 (1) 
0.81 (0.670.99) 
1.17 (1.091.25) 
1.35 (1.251.45) 
1.24 (1.021.52) 
Maternal age 
Parity 
Race 
 
Kistka et al 
200730  
USA 
Retrospective 
Cohort 
368,633:Not 
reported 
19891997 BMI, method 
of assessment 
not reported 
Not reported 3741+6 * 
≥42 
 
Reference 
not defined+ 
<20 
>35 
Not reported Not reported 1 (1) 
0.90 (0.880.93) 
1.25 (1.191.32) 
1 (1) 
0.85 (0.820.87) 
1.23 (1.161.29) 
Socioeconomic status 
Maternal medical risk 
factors 
Year of delivery 
Kitiyodom and 
Tongswatwong 
200831  
Thailand 
Retrospective 
Cohort 
1,350:166 10/2004
09/2006 
Early 
pregnancy 
measured BMI 
USS + LMP Reference 
not defined+ 
Postterm 
not defined 
2024.9+ 
>25 
1,020 
330 
110 
56 
1 (1) 
1.7 (1.192.44) 
 
Not reported N/A 
Knight et al 
201032  
UK 
Prospective 
Cohort 
1,280:56 09/2007
08/2008 
Pregnancy 
measured BMI 
Not reported Reference 
not defined + 
>42 
 
<50+ 
≥50 
630 
650 
24 
32 
1 (1) 
1.31 (0.762.25) 
1 (1) 
1.35 (0.772.37) 
Maternal age 
Parity 
Socioeconomic status 
Ethnicity 
Smoking 
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Author, 
publication 
year, region, 
country  
 
Methodology Number of 
participants: 
number of 
cases
1
 
Study 
period 
 
Assessment 
of weight 
status 
Assessment 
of gestational 
age 
Gestational 
age groups 
(weeks) 
BMI (kg/m
2
)  
or weight 
category 
Participants 
per BMI 
category 
Cases per 
BMI 
category 
Crude analysis 
(OR and 95% CI 
unless otherwise 
specified) 
Adjusted analysis 
(OR and 95% CI 
unless otherwise 
specified) 
Variables included in 
adjusted analyses 
Konje et al 
199333 
UK 
Case Control 760:14 01/1989
06/1990 
Early 
pregnancy 
measured BMI 
USS 3742 * 
>42 
1724+ 
30.453.0 
299 
461 
11 
3 
Not reported Not reported N/A 
Leung et al 
200834  
Hong Kong 
Retrospective 
Cohort 
27,372:4,118 01/1995
12/2005 
Early 
pregnancy BMI 
Not reported 3740+6 * 
≥41 
18.5<23+ 
<18.5 
≥23<25 
≥25<27.5 
≥27.5<30 
≥30 
16,303 
2,434 
4,346 
2,617 
1,062 
610 
2,430 
322 
654 
429 
175 
108 
Not reported 1 (1) 
0.84 (0.740.95) 
1.06 (0.971.17) 
1.21 (1.081.36) 
1.25 (1.051.48) 
1.34 (1.091.66) 
 
Only included Chinese 
ethnicity. Adjusted for 
confounding factors, not 
specified. 
Lumme et al 
199535 
Finland 
Prospective 
Cohort 
8,719:439 07/1985
06/1986 
Early 
pregnancy 
measured BMI 
Not reported 3741 * 
>41 
1924.9+ 
<19 
2529.9 
≥30 
1,037 
6,173 
1,177 
332 
136 
228 
63 
12 
Not reported 1 (1) 
1.0 (0.71.4) 
1.6 (1.22.1) 
1.1 (0.61.9) 
Maternal age 
Parity 
Education 
Smoking 
Diabetic and 
Hypertensive 
complications 
Mancuso et al 
199136  
Italy 
Case Control 138:4 Not reported Selfreport pre
pregnancy BMI 
Not reported 3841 *  
>42 
15.226.6+ 
>30 
82 
56 
1 
3 
Not reported Not reported N/A 
Manzanares et 
al 201237  
Spain 
Case Control 2,714:196 20072009 Early 
pregnancy 
measured BMI 
Not reported 3741+2  * 
>41+3 
18.525+ 
<18.5 
>35 
2,341 
147 
226 
174 
12 
10 
Not reported 1 (1) 
0.81 (0.351.91) 
0.72 (0.341.55) 
Maternal age 
Parity 
Hypertension 
Diabetes 
Morgan et al 
201438 
UK 
Prospective 
Cohort 
440:28 11/2010
02/2013 
Prepregnancy 
BMI, method 
of assessment 
not reported# 
USS Reference 
not defined + 
=42 
18.524.9+ 
2529.9 
>29.9 
234 
 
206 
10 
 
18 
1 (1) 
 
2.18 (0.994.84) 
Not reported N/A 
Navid et al 
201339 
Pakistan 
Case Control 200:57 05/2011 
07/2012 
Early 
pregnancy 
BMI, method 
of assessment 
not reported 
USS 3740* 
>40 
1824.9+ 
2535 
100 
100 
25 
32 
Not reported Not reported N/A 
Nohr et al 200940 
Denmark 
Prospective 
Cohort 
4,700:1,541 
 
 
19962002 Selfreported 
prepregnancy 
BMI 
Not reported 3741* 
>41 
1533.3+ 
32.6<35 
35<37.5 
≥37.5 
2,354 
853 
721 
770 
688 
292 
277 
283 
Not reported 1 (1) 
1.3 (1.11.5) 
1.5 (1.31.8) 
1.4 (1.21.7) 
Age 
Parity 
Maternal height 
Smoking 
Alcohol consumption 
Physical exercise 
Social group 
Olesen et al 
200641  
Denmark 
Retrospective 
Cohort 
47,338:5,227 19962004 BMI –self 
reported 
LMP + USS 37 41+6  * 
≥42 
2024+ 
<20 
2529 
3034 
≥35 
26,486 
7,918 
9,201 
2,713 
1,020 
2,800 
736 
1,165 
374 
152 
1  
0.87  
1.23  
1.35  
1.48 
95%CI not 
reported 
1 (1) 
0.87 (0.800.94) 
1.24 (1.151.34) 
1.37 (1.221.54) 
1.52 (1.281.82) 
Maternal age 
Parity 
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Author, 
publication 
year, region, 
country  
 
Methodology Number of 
participants: 
number of 
cases
1
 
Study 
period 
 
Assessment 
of weight 
status 
Assessment 
of gestational 
age 
Gestational 
age groups 
(weeks) 
BMI (kg/m
2
)  
or weight 
category 
Participants 
per BMI 
category 
Cases per 
BMI 
category 
Crude analysis 
(OR and 95% CI 
unless otherwise 
specified) 
Adjusted analysis 
(OR and 95% CI 
unless otherwise 
specified) 
Variables included in 
adjusted analyses 
Raatikainen et al 
200642  
Finland 
Retrospective 
Cohort 
25,601:1,233 01/1989 
12/2001 
Early 
pregnancy 
measured BMI 
Not reported Reference 
not defined +   
>42 
≤25+ 
2629 
≥30 
20,333 
3,388 
1,880 
935 
193 
105 
Not reported Not reported N/A 
Robinson  et al 
200543  
Canada 
Retrospective 
Cohort 
84,055:5,689 01/1988 
12/1992 
Prepregnancy 
BMI, method 
of assessment 
not reported# 
Not reported Reference 
not defined + 
>41  
5575Kg+ 
≥90120Kg 
>120Kg 
74,566 
8,774 
715 
4,997 
647 
45 
1 (1) 
1.10 (1.011.20) 
0.91 (0.671.23) 
1 (1) 
1.18 (1.081.28) 
0.99 (0.741.34) 
Maternal age 
Marital status 
Parity 
Smoking 
Socioeconomic status 
Rode et al 
200544 
Denmark 
Prospective 
Cohort 
8,463:Not 
reported 
1998  2001 Selfreport pre
pregnancy BMI 
USS 3742*  
>42 
<25+ 
2529.9 
≥30 
Not reported Not reported Not reported 1 (1) 
1.4 (1.21.7) 
1.4 (1.11.9) 
Maternal age 
Smoking 
Ethnic background 
Type of conception 
Roos et al 
201045 
Sweden 
Retrospective 
Cohort 
972,883: 
85,488 
01/1992 
12/2006 
Early 
pregnancy 
measured BMI 
USS + LMP 3741+6* 
≥42 
2024.9+ 
<20 
2529.9 
≥30 
560,667 
105,643 
224,550 
82,013 
46,323 
6,486 
22,834 
9,845 
Not reported 1 (1) 
0.74 (0.720.76) 
1.31 (1.291.33) 
1.63 (1.591.67) 
Maternal age 
Parity 
Education 
BMI 
Smoking 
Country of origin 
Mother living with father 
Schrauwers and 
Dekker 200946 
Australia 
Retrospective 
Cohort 
348:3 01/2006 
06/2006 
Early 
pregnancy 
BMI, method 
of assessment 
not reported 
Not reported 3741* 
>41 
19.125+ 
25.130 
30.140 
>40 
93 
92 
108 
55 
0 
1 
2 
0 
Not reported Not reported N/A 
ScottPillai et al 
2013 47 
UK 
Retrospective 
Cohort 
30,298:Not 
reported 
20042011 Early 
pregnancy 
measured BMI 
Not reported Reference 
not defined + 
>41 
18.524.99+ 
<18.50 
2529.99 
3034.99 
3539.99 
≥40 
Not reported Not reported Not reported 1 (1) 
0.5 (0.21.0) 
0.9 (0.71.1) 
0.8 (0.51.1) 
0.9 (0.51.6) 
0.8 (0.41.7) 
Age 
Parity 
Year of birth 
Social deprivation 
Smoking 
Sharief and Tarik 
200048 
Iraq 
Prospective 
Cohort 
40:6 12/1997
08/1998 
Early 
pregnancy 
measured 
weight 
Not reported Reference 
not defined + 
Postterm 
not defined 
<=90Kg 
>90Kg 
20 
20 
3 
3 
Not reported Not reported N/A 
Stotland et al 
200749 
USA 
Retrospective 
Cohort 
10,878:2,402  
 
 
 
 
10,878:595  
19902001 Selfreport pre
pregnancy BMI 
USS + LMP 37<41* 
≥41 
 
 
 
37<42* 
≥42 
19.826+ 
<19.8 
26.129 
>29 
6,477 
2,171 
1,213 
1,017 
 
6,477 
2,171 
1,213 
1,017 
1,418 
397 
297 
290 
 
350 
83 
89 
73 
Not reported 1 (1) 
0.83 (0.720.95) 
1.29 (1.101.52) 
1.81 (1.502.18) 
 
1 (1) 
0.78 (0.601.01) 
1.51 (1.151.97) 
1.69 (1.232.31) 
Maternal age 
Ethnicity 
Parity 
Gestational weight gain 
Insurance status 
Hypertension 
Diabetes 
Smoking 
Usha Kiran et al 
200550 
UK  
Retrospective 
Cohort 
8,350:2,768 19901999 Early 
pregnancy 
measured BMI 
USS 3741*  
>41 
2030+ 
>30 
7,673 
677 
2,490 
278 
1 (1) 
1.4 (1.21.7) 
Not reported N/A 
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Author, 
publication 
year, region, 
country  
 
Methodology Number of 
participants: 
number of 
cases
1
 
Study 
period 
 
Assessment 
of weight 
status 
Assessment 
of gestational 
age 
Gestational 
age groups 
(weeks) 
BMI (kg/m
2
)  
or weight 
category 
Participants 
per BMI 
category 
Cases per 
BMI 
category 
Crude analysis 
(OR and 95% CI 
unless otherwise 
specified) 
Adjusted analysis 
(OR and 95% CI 
unless otherwise 
specified) 
Variables included in 
adjusted analyses 
Vaswani and 
Balachandran 
201351 
United Arab 
Emirates 
Retrospective 
Cohort 
1,985:147 12/2010 
10/2011 
Early 
pregnancy 
measured BMI 
Not reported 3741* 
>41 
18.524.9+ 
2529.9 
3034.9 
3539.9 
≥40 
420 
635 
520 
280 
130 
20 
48 
43 
24 
12 
Not reported 1 (1) 
1.54 (0.892.65) 
1.69 (0.962.98) 
1.78 (0.933.42) 
2.99 (1.356.65) 
Age 
Parity 
Hypertension 
Diabetes 
Vinturache et al 
201452 
Canada 
Prospective 
Cohort 
1,996:5 05/2008 
12/2010 
Selfreport pre
pregnancy BMI 
Not reported 3741+6 * 
≥42 
18.524.99+ 
2529.99 
≥30 
1,313 
472 
211 
4 
1 
0 
Not reported Not reported N/A 
Voigt et al 
200853 
Germany 
Retrospective 
Cohort 
303,960: 
34,266 
19982000 Prepregnancy 
BMI, method 
of assessment 
not reported# 
Not reported Term, not 
defined + 
Postterm, 
not defined 
18.524.99+ 
4044.99 
≥45 
300,299 
2,946 
715 
33,703 
452 
111 
Not reported Not reported N/A 
Yazdani et al 
200654 
Iran 
Retrospective 
Cohort 
966:33 20082009 Early 
pregnancy 
BMI, method 
of assessment 
not reported 
USS + LMP Term, not 
defined + 
Postterm, 
not defined 
2024.9+ 
≤19.9 
2529.9 
3034.9 
>35 
403 
126 
340 
92 
5 
14 
4 
12 
3 
0 
Not reported Not reported N/A 
Footnote: 1 In studies which presented data for preterm, term and postterm births, the numbers of participants and cases were calculated following exclusion 
of preterm births when possible. #Weight assessment is presumed to be selfreported as prepregnancy BMI was used, although this was not explicitly 
stated. + Reference group for BMI. * Reference group for gestational age. Abbreviations: BMI = body mass index; CI = confidence interval; IQR = inter quartile 
range; LMP = last menstrual period; N/A = not applicable; OR = odds ratio; RR = relative risk; USS = ultrasound scan 
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Table S4: Contacting authors for additional information 
Paper 
 
Reason For Contacting Original Data 
(BMI Kg/m
2
) 
Original Data 
(Participants:Cases) 
Author Response
#
 
 
Definitions 
Provided 
Data Provided 
(BMI Groups) 
Data Provided 
(Participants:Cases) 
Abenhaim et al 
2007
16 
 To provide frequencies for cases^  
 Split BMI 30-39.9 into WHO obesity 
classes I and II  
20-24.9 
 
<19.9 
 
25-29.9  
30-39.9  
>40 
10,015:not reported 
4,310:not reported 
3,067:not reported 
1,137:not reported 
104:not reported 
Unable to provide 
data 
N/A N/A Not provided
|
 
Al-Rayyan et al 
2010
17 
 To provide frequencies according to 
specified WHO BMI categories^ 
<30
 
>30 
461:55 
440:54 
No response N/A N/A Not provided
|
 
Arora et al 2013
18
  To provide frequencies for WHO 
BMI categories >30 
>30        188:1 Additional data 
provided 
N/A 30-34.9 
35-39.9 
≥40 
159:0 
35:0 
9:1 
Arrowsmith et al 
2011
19
 
 To provide frequencies for 
participants and cases^ 
20-24.9
 
<19.9 
 
25-29.9  
30-34.9 
35-39.9  
>40 
Not reported Additional data 
provided 
N/A 20-24.9
+ 
<19.9 
 
25-29.9  
30-34.9 
35-39.9  
>40 
9,374:2,193 
2,002:367 
5,262:1,428 
2,028:634 
697:234 
298:123 
Basu et al 2010
20
  Split BMI 30-39.9 into WHO obesity 
classes I and II 
30-39.9    
 
298:49 
 
No response N/A N/A Not provided 
Bhattacharya et al 
2007
21
 
 Definition used for comparison 
group for gestational age 
N/A N/A Definition provided 37-42 
 
N/A N/A 
Briese et al 2011
22 
 Definition for gestational age 
reference group 
 Definition used for post-term 
 To provide frequencies for 
participants and cases^ 
18.5-24.9 
≥30 
Not reported Provided definitions. 
Unable to provide 
frequencies. 
>37-<42 
≥42 
N/A Not provided
|
 
Caughey et al 
2009
23 
 To provide frequencies according to 
specified WHO BMI categories^ 
Not reported Not reported Unable to provide 
data 
N/A Not provided Not provided
|
 
Cedergren 2004
24
  To provide frequencies the BMI 
category >26-29. 
19.8-26 
29.1-35 
35.1-40 
>40 
501,954:37,640 
64,286:6,072 
11,605:1,197 
3,125:379 
Additional data 
provided 
N/A 26.1-29 
 
95,675:8,381 
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Paper 
 
Reason For Contacting Original Data 
(BMI Kg/m
2
) 
Original Data 
(Participants:Cases) 
Author Response
#
 
 
Definitions 
Provided 
Data Provided 
(BMI Groups) 
Data Provided 
(Participants:Cases) 
Denison et al 
2008
25 
 To provide frequencies according to 
specified WHO BMI categories^ 
20-24.9 
<20 
25-29.9 
30-34.9 
≥35 
Not reported Unable to provide 
data 
N/A N/A 
 
Not provided
|
 
El-Gilany and 
Hammad 2010
26
 
 Split BMI ≥30 into WHO obesity 
classes 
≥30 226:11 Additional data 
provided 
N/A 30-34.9 
35-39.9 
≥40 
138:1 
59:4 
29:6 
Halloran et al 
2012
27
 
 Split BMI ≥30 into WHO obesity 
classes for 41 and 42 weeks 
gestation 
41 
≥30 
42 
≥30 
 
62,924:10,356 
 
62,924:2,676 
Additional data 
provided 
N/A 41 
30-34.9 
35-39.9 
≥40 
42 
30-34.9 
35-39.9 
≥40 
 
35,767:5,832 
16,802:2,741 
10,355:1,777 
 
35,767:1,491 
16,802:743 
10,355:442 
Johnson et al 
1992
28
 
 Split BMI >29 into WHO obesity 
classes 
>29 486:56 Unable to provide 
data 
N/A N/A Not provided 
Khashan and 
Kenny 2009
29
 
 Split BMI 30-40 into WHO obesity 
classes  
 Definition of gestational age 
reference group 
30-40 
 
12,489:897 
 
Additional data 
provided 
37-<42 30-34.9 
35-39.9 
 
9,983:650 
3,574:247 
Kistka et al 2007
30 
 Definition of BMI reference group  
 To provide frequency data^ 
 
Reference 
group not 
reported 
<20 
>35 
Not reported 
 
Unable to provide 
data 
 
N/A N/A 
 
Not provided
|
 
Kitiyodom and 
Tongswatwong 
2008
31
 
 Split BMI >25 into WHO categories^ 
 Definition of gestational age 
reference group and post-term 
>25 330:56 Additional data 
provided 
37-<42 
≥42 
25-29.9 
30-34.9 
35-39.9 
≥40 
211:25 
52:24 
21:6 
2:1 
Knight et al 
2010
32
 
 Split BMI <50 into WHO categories^ 
 Definition of gestational age 
reference group 
<50 
 
630:24 
 
Additional data 
provided 
37-<42 
 
18.5-24.9
+
 
<18.5 
25-29.9 
30-34.9 
35-39.9 
≥40 
267:12 
15:0 
173:7 
77:3 
28:2 
11:0 
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Paper 
 
Reason For Contacting Original Data 
(BMI Kg/m
2
) 
Original Data 
(Participants:Cases) 
Author Response
#
 
 
Definitions 
Provided 
Data Provided 
(BMI Groups) 
Data Provided 
(Participants:Cases) 
Konje et al 1993
33
  To provide frequencies for specific 
BMI groups >25 
Not reported 299:11 
461:3 
Unable to provide 
data 
 
N/A Not provided 
 
Not provided 
Leung et al 2008
34
  To provide frequencies for specific 
BMI groups >30 
≥30 610:108 No response  N/A N/A Not provided 
Lumme et al 
1995
35
 
 To provide frequencies for specific 
BMI groups >30 
≥30 332:12 No response 
 
N/A N/A 
 
Not provided 
Mancuso et al 
1991
36 
 To provide frequencies according to 
specified WHO BMI categories^ 
15.2-26.6 
>30 
82:1 
56:3 
No response  N/A N/A 
 
Not provided
|
 
Manzanares et al 
2012
37
 
 To provide frequencies for BMI 
groups 25-29.9, 30-34.9, 35-39.9, 
≥40 
18.5-25 
>35 
2,341:174 
226:10 
Additional data 
provided 
N/A 25-29.9 
30-34.9 
35-39.9 
≥40 
914:64 
321:19 
129:6 
86:4 
Morgan et al 
2014
38
 
 To provide frequencies for BMI 
groups 25-29.9  
 Split >29.9 into WHO obesity classes  
 Definition for gestational age 
reference group. 
18.5-24.9 
>29.9 
234:10 
206:18 
Provided definition 
for gestational age. 
Unable to provide 
frequency data 
37-<42 
 
N/A 
 
Not provided 
Navid et al 2013
39 
 Split BMI group 25-35^ 18-24.9
+
 
25-35 
100:25 
100:32 
No response N/A N/A Not provided
|
 
Nohr et al 2009
40
  To provide frequencies according to 
specified WHO BMI categories^ 
15-33.3 
32.6-<35 
35-<37.5 
≥37.5 
2,354:688 
853:292 
721:277 
770:283 
Additional data 
provided 
N/A 18.5-24.9
 
<18.5 
25-29.9 
30-34.9 
35-39.9 
≥40 
1,261:71 
87:3 
332:17 
677:40 
731:50 
272:22 
Olesen et al 
2006
41
 
 Split BMI ≥35 ≥35 1,020:154 Unable to provide 
data 
 
N/A N/A 
 
Not provided 
Raatikainen et al 
2006
42
 
 Split BMI ≥30 into obesity classes I-
III 
 Definition for gestational age 
reference group 
≤25 
26-29 
≥30 
20,333:935 
3,388:193 
1,880:105 
No response Not provided*
 
Not provided  Not provided 
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Paper 
 
Reason For Contacting Original Data 
(BMI Kg/m
2
) 
Original Data 
(Participants:Cases) 
Author Response
#
 
 
Definitions 
Provided 
Data Provided 
(BMI Groups) 
Data Provided 
(Participants:Cases) 
Rode et al 2005
44
  To provide frequencies of 
participants and cases according to 
specified WHO BMI categories^ 
<25
+ 
25-29.9 
≥30 
Not reported Additional data 
provided 
N/A 18.5-24.9
 
<18.5 
25-29.9 
30-34.9 
35-39.9 
≥40 
5,986:567 
364:25 
1,298:162 
326:39 
81:12 
37:3 
Roos et al 2010
45
  Split BMI ≥30 into obesity classes I-
III 
≥30 82,013:9,845 Unable to provide 
data 
N/A Not provided  Not provided 
Scott-Pillai et al 
2013
47
 
 To provide frequencies of 
participants and cases^ 
 Definition for gestational age 
reference group 
18.5-24.99 
<18.50 
25-29.99 
30-34.99 
35-39.99 
≥40 
Not reported Additional data 
provided 
>37-41 18.5-24.99 
<18.50 
25-29.99 
30-34.99 
35-39.99 
≥40 
15,046:3,261 
803:149 
7,917:1,776 
3,120:667 
1,121:238 
541:121 
Stotland et al 
2007
49
 
 To split BMI groups >29 into obesity 
classes I-III for both 41 and 42 weeks 
gestation 
41 
>29 
 
42 
>29 
 
1,017:290 
 
 
1,017:73 
Unable to provide 
data 
 
N/A N/A 
 
 
Not provided 
Usha Kiran et al 
2005
50 
 To split BMI groups 20-30 and >30 
according to WHO BMI categories^ 
20-30 
>30 
7,673:2,490 
677:278 
Unable to provide 
data 
 
N/A N/A 
 
Not provided
|
 
Voigt et al 2008
53
  To provide frequencies for WHO 
categories between 25 and 39.9  
 Definitions for gestational age 
reference group and post-term 
18.5-24.99
+
 
40-44.99 
≥45 
300,299:33,703 
2,946:452 
715:11 
Provided definitions. 
Unable to provide 
frequencies. 
37-<42 
≥42 
Not provided Not provided 
Yazdani et al 
2006
54
 
 Definitions for gestational age 
reference group and post-term 
N/A N/A No response Not provided*
 
N/A N/A 
Footnote: # Nonresponding authors contacted up to three times 
^ Essential data request for inclusion in metaanalysis 
| Excluded from metaanalysis after contacting author, due to lack of essential data,  
* Assumptions made as per methods section of manuscript. 
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Table S5: Quality scores for all included studies 
 
Paper Newcastle Ottawa Scale Question number and score allocated Independent 
reviewer initials 1 2 3 4 5 6 7 Total 
Stars 
Abenhaim et al 2007 16 a * a * c b * d b c 3 LC & LH 
AlRayyan et al 2010 17 d a * a * c d b d 2 LC & NH 
Arora et al 2013 18 b * a * d c d b b * 3 NH & LH 
Arrowsmith et al 2011 19 a * a * a * a&b** b * a * b * 8 LC & NH 
Basu et al 2010 20 b * a * d c b * b d 3 NH & LH 
Bhattacharya et al 2007 21 c a * a * b * b * b b * 5 JR & LH 
Briese et al 201122 a * a * d b * d b a * 4 LC & NH 
Caughey et al 2009 23 a * a * d b * d a * d 4 LH & NH 
Cedergren 2004 24 a * a * d b * b * b b * 5 NH & LH 
Denison et al 2008 25 a * a * a * c b * a * c 5 LC & LH 
El Gilany & Hammad 2010 26 a * a * a * c c  c 3 LC & LH 
Halloran et al 2012 27 a * a * c b * b * b b * 5 LC & NH 
Johnson et al 1992 28 b * a * c b * b * b b * 5 LC & NH 
Khashan & Kenny 2009 29 a * a * a * b * b * b c 5 LC & NH 
Kistka et al 2007 30 c a * d b * b * b b * 4 LH & JR 
Kitiyodom & Tongswatwong 
2008 31 
d a * a * c b * b d 3 NH & RV 
Knight et al 2010 32 b * a * d b * d b b * 4 LC & NH 
Konje et al 1993 33 c a * a * b * b * b d 4 NH & LH 
Leung et al 2008 34 a * a * d b * d b b * 4 LC & LH 
Lumme et al 1995 35 a * a * b * c d b b * 4 LC & NH 
Mancuso et al 1991 36 d a * d c d b d 1 LC & NH 
Manzanares et al 2012 37 a * a * a * b * d b c 4 LC & NH 
Morgan et al 2014 38 b * a * d b * b * b c 4 LC & LH 
Navid et al 2013 39 d a * d c a * b d 2 NH & LH 
Nohr et al 2009 40 b * a * c b * d b b * 4 NH & LH 
Olesen et al 2006 41 b * a * c b * c b d 3 LH & LC 
Raatikianen et al 2006 42 a * a * a * b * d b b * 5 LH & JR 
Robinson et al 2005 43 a * a * d b * d b b * 4 NH & LH 
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Paper Newcastle Ottawa Scale Question number and score allocated Independent 
reviewer initials 1 2 3 4 5 6 7 Total 
Stars 
Rode et al 2005 44 b * a * c b * a * b b * 5 NH & LC 
Roos et al 2010 45 a * a * a * a&b** b * a * b * 8 NH & LH 
Schrauwers & Dekker 2009 46 b * a * d c d b d 2 LH & NH 
ScottPillai et al 2013 47 a * a * a * a&b** d a * b * 7 LC & NH  
Sharief & Tarik 2000 48 c a * a * b * d b d 3 LH & NH 
Stotland et al 2007 49 a * a * d a&b** b * a * d 6 NH & JR 
Usha Kiran et al 2004 50 c a * a * c b * b b * 4 LC & JR 
Vaswani and Balachandran 
2013 51 
a * a * a * b * d b d 4 LH & NH 
Vinturache et al 2014 52 b * a * c b * d a * b * 5 NH & LH 
Voigt et al 2008 53 a * a * d c d b d 2 LC & NH 
Yazdani et al 2012 54 c a * d c b * b c 2 NH & RV 
Footnote: NewcastleOttawa question numbers 17, answers ad, and associated number of stars (*) are detailed in fig. S2. Minimum number of possible 
stars to be awarded = 0, maximum number of possible stars to be awarded = 8. Reviewers initials relate to manuscript authors JR: Judith Rankin, LC: Lisa 
Crowe, LH: Louise Hayes, NH: Nicola Heslehurst, and RV: Rute Vieira.  
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Figure S3: Exploration of the use of adjusted or unadjusted data for post4term 
birth (≥ 42 weeks and ≥ 41 weeks) meta4analysis 
 
Figure S3a) Association between maternal BMI and post4term birth ≥42 weeks: unadjusted 
data 
 
 
Figure legend: Metaanalysis of the four studies which provided both unadjusted and adjusted data for 
maternal BMI and postterm birth, showing the overall effect size (OR) and 95% confidence interval 
for the association when using the unadjusted data to compute the OR for the continuous BMI. 
Abbreviations: OR = odds ratio; BMI = body mass index; n = number of individuals. 
 
 Figure S3b) Association between maternal BMI and post4term birth ≥42 weeks: adjusted data 
 
Figure legend: Metaanalysis of the four studies which provided both unadjusted and adjusted data for 
maternal BMI and postterm birth, showing the overall effect size (OR) and 95% confidence interval 
for the association when using the adjusted data to compute the OR for the continuous BMI. 
Abbreviations: OR = odds ratio; BMI = body mass index; n = number of individuals. 
 
 
 
 
 
 
 
Overall  (Isquared = 98.2%, p = 0.000)
Stotland et al 2007 49 
Roos et al 2010 45 
Olesen et al 2006 41 
Cedergren  et al 2004 24
10878
972873
47338
676645
595 
85488
5227
53669
1.21 (1.13, 1.29)
1.29 (1.16, 1.44)
1.26 (1.25, 1.27)
1.17 (1.13, 1.20)
1.15 (1.14, 1.16)
.2 .5 1 1.5 2 2.5
Source Participants
(n) 
OR per 5 BMI units
(95% CI)
Post4term 
≥42 weeks (n)
1.24 (1.15, 1.33)
1.17 (1.13, 1.21)
1.30 (1.29, 1.31)
1.35 (1.20, 1.53)
1.18 (1.17, 1.20)
Stotlandet al 2007 49
Roos et al 2010 45
Olesen et al 2006 41
Cedergren  et al 2004 24
10878
972873
47338
676645
595
85488
5227
53669
Overall  (Isquared = 98.3%, p = 0.000)
Source Participants
(n)
Post4term  
≥42 weeks (n)
OR per 5 BMI units
(95% CI)
.2 .5 1 1.5 2 2.5
Page 66 of 106
World Obesity Journals
Obesity Reviews
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
27 
 
Figure S3c) Association between maternal BMI and post4term birth ≥41 weeks: unadjusted 
data 
 
    
Figure legend: Metaanalysis of the four studies which provided both unadjusted and adjusted data for 
maternal BMI and postterm birth, showing the overall effect size (OR) and 95% confidence interval 
for the association when using the unadjusted data to compute the OR for the continuous BMI. 
Abbreviations: OR = odds ratio; BMI = body mass index; n = number of individuals. 
 
 
     Figure S3d) Association between maternal BMI and post4term birth ≥41 weeks: adjusted data  
 
 
Figure legend: Metaanalysis of the four studies which provided both unadjusted and adjusted data for 
maternal BMI and postterm birth, showing the overall effect size (OR) and 95% confidence interval 
for the association when using the adjusted data to compute the OR for the continuous BMI. 
Abbreviations: OR = odds ratio; BMI = body mass index; n = number of individuals; CI = confidence 
interval. 
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Figure S4: Sensitivity analysis for transforming Asian4specific BMI reference 
criteria for the analysis of maternal BMI and post4term birth ≥41 weeks  
 
Figure S4a) Association between maternal BMI and post4term birth using Asian4specific BMI 
criteria for Leung et al
34 
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Figure S4b) Association between maternal BMI and post4term birth using General population 
BMI criteria for Leung et al
34 
 
 
 
Figure legend: Sensitivity analysis exploring the influence of using the Asianspecific BMI criteria for 
the study by Leung et al 34 on the overall effect size (OR) and 95% confidence interval for the 
association between maternal BMI and postterm birth ≥41 weeks. Abbreviations: OR = odds ratio; 
BMI = body mass index; n = number of individuals; CI = confidence interval. 
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Table S6: Nonlinear meta4analyses using cubic splines regression 
a) Post4term birth ≥42 weeks  
                                             Number of observations  =    17   
  Coef. Std. err. z P 95% Confidence Interval 
Overall   
  spline1 0.0479 0.0096 5.00   <0.001 0.0291 0.0667 
  spline2 0.0302 0.0099 3.06 0.002 0.0495 0.0108 
 
b) Post4term birth ≥41 weeks  
                                               Number of observations  =    11   
  Coef. Std. err. z P 95% Confidence Interval 
Overall   
  spline1 0.020952 0.007184 2.92 0.004     0.006873 0.0350315 
  spline2 0.003860 0.003193 1.21 0.227    0.010119 0.0023986 
 
 
c) Post4term birth ≥41 weeks including Lumme et al
35
 
                                               Number of observations  =    11   
  Coef. Std. err. z P 95% Confidence Interval 
Overall   
  spline1 0.03685 0.011754 3.14 0.002 0.013812 0.059888 
  spline2 0.04136 0.022377 1.85 0.065 0.08521 0.002503 
 
Footnote: Nonlinearity was assessed by testing that the coefficient of the second spline was equal to 
zero. 
Abbreviations:  z = value for the z statistic 
  Coef. = coefficient 
          Std. Err. = Standard error 
  P = pvalue 
 
  
Page 70 of 106
World Obesity Journals
Obesity Reviews
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
31 
 
Table S7: Egger’s test for publication bias for post4term birth (≥ 42 weeks and 
≥41 weeks)  

 
 Std_Eff Coef. Std. Err.      t P     [95% Conf. Interval] 
≥ 42 
weeks 
       slope .1796733    .0287235     6.26    0.000       .119072     .2402747 
        bias 1.150876    2.149826     0.54    0.599     5.686613     3.38486 
Test of H0: no smallstudy effects P = 0.599, Number of studies = 19, Root MSE = 7.443 
≥ 41 
weeks 
       slope .0439365 .0175043     2.51    0.033       .004339 .083534 
        bias 2.066102    1.355701     1.52    0.162     1.000708    5.132911 
Test of H0: no smallstudy effects P = 0.162, Number of studies = 11, Root MSE = 3.768 
Footnote: Egger's test for smallstudy effects: Regression of the standard normal deviate of 
intervention effect estimate against its standard error.  
 
Abbreviations: Std_Eff = standard normal deviate of intervention effect 
         Coef. = coefficient 
         Std. Err. = Standard error 
         t = tstatistics 
         P = pvalue 
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Table S8: Maternal BMI and post4term birth ≥ 42 weeks sensitivity analysis 
 
 Linear 
analyses  
OR  
(95% CI) 
Nonlinear Analyses: BMI Midpoint (kg/m
2
) 
OR (95% CI) 
Model 5 BMI 
units 
17.5 22.5 27.5 32.5 37.5 42.5 47.5 
Arora et al 
2013 18 
1.19 
(1.12,1.27) 
0.80 
(0.74,0.87) 
1 1.24 
(1.15,1.34) 
1.42 
(1.28,1.58) 
1.54 
(1.37,1.73) 
1.62 
(1.42,1.85) 
1.71 
(1.46,1.99) 
Bhattacharya 
et al 2007 21 
1.19 
(1.11,1.26) 
0.81 
(0.74,0.89) 
1 1.24 
(1.14,1.34) 
1.41 
(1.26,1.59) 
1.55 
(1.36,1.76) 
1.65 
(1.44,1.90) 
1.76 
(1.50,2.06) 
Cedergren et 
al 2004 24 
1.19 
(1.11,1.28) 
0.80 
(0.72,0.89) 
1 1.25 
(1.14,1.38) 
1.44 
(1.25,1.66) 
1.57 
(1.34,1.85) 
1.67 
(1.40,2.00) 
1.77 
(1.44,2.17) 
ElGilani et al 
2009 26 
1.17 
(1.10,1.25) 
0.82 
(0.73,0.89) 
1 1.23 
(1.14,1.32) 
1.40 
(1.26,1.56) 
1.53 
(1.36,1.72) 
1.63 
(1.45,1.84) 
1.74 
(1.54,1.97) 
Halloran et al 
2012 27 
1.20 
(1.14,1.27) 
0.79 
(0.75,0.83) 
1 1.26 
(1.21,1.32) 
1.45 
(1.36,1.55) 
1.59 
(1.45,1.75) 
1.70 
(1.48,1.94) 
1.80 
(1.48,1.94) 
Johnson et al 
1992 28 
1.19 
(1.12,1.27) 
0.80 
(0.74,0.88) 
1 1.24 
(1.15,1.34) 
1.42 
(1.27,1.58) 
1.53 
(1.36,1.73) 
1.62 
(1.42,1.85) 
1.70 
(1.46,1.99) 
Kashan et al 
2009 29 
1.20 
(1.12,1.28) 
0.81 
(0.74,0.89) 
1 1.24 
(1.14,1.34) 
1.43 
(1.27,1.60) 
1.58 
(1.38,1.80) 
1.71 
(1.48,1.97) 
1.84 
(1.56,2.17) 
Kitiyodom et 
al 2008 31 
1.16 
(1.10,1.24) 
0.83 
(0.76,0.90) 
1 1.21 
(1.12,1.31) 
1.37 
(1.23,1.54) 
1.50 
(1.32,1.69) 
1.59 
(1.40,1.82) 
1.69 
(1.47,1.96) 
Konje et al 
1993 33 
1.21 
(1.14,1.28) 
NA NA NA NA NA NA NA 
Knight et al 
2010  32 
1.19 
(1.12,1.26) 
0.81 
(0.74,0.87) 
1 1.24 
(1.15,1.34) 
1.42 
(1.27,1.58) 
1.55 
(1.37,1.75) 
1.65 
(1.44,1.89) 
1.75 
(1.49,2.04) 
Morgan et al 
2014 38 
1.18 
(1.12,1.26) 
NA NA NA NA NA NA NA 
Olesen et al 
2006 41 
1.19 
(1.12,1.27) 
0.80 
(0.73,0.88) 
1 1.25 
(1.15,1.35) 
1.43 
(1.27,1.61) 
1.55 
(1.36,1.78) 
1.65 
(1.43,1.90) 
1.74 
(1.48,2.05) 
Raatikainen et 
al 2006 42 
1.19 
(1.12,1.27) 
0.80 
(0.74,0.88) 
1 1.24 
(1.15,1.34) 
1.42 
(1.27,1.60) 
1.55 
(1.37,1.77) 
1.67 
(1.44,1.90) 
1.76 
(1.50,2.06) 
Rode et al 
2005 44 
1.19 
(1.12,1.26) 
0.81 
(0.74,0.89) 
1 1.23 
(1.14,1.33) 
1.41 
(1.26,1.58) 
1.54 
(1.36,1.75) 
1.64 
(1.43,1.89) 
1.75 
(1.49,2.05) 
Roos et al 
2010 45 
1.17 
(1.12,1.23) 
0.81 
(0.74,0.89) 
1 1.23 
(1.14,1.33) 
1.40 
(1.25,1.57) 
1.51 
(1.34,1.57) 
1.60 
(1.38,1.85) 
1.68 
(1.40,2.02) 
Stotland et al 
2007 49 
1.18 
(1.11,1.25) 
0.81 
(0.74,0.89) 
1 1.23 
(1.14,1.33) 
1.40 
(1.25,1.56) 
1.52 
(1.34,1.72) 
1.61 
(1.41,1.85) 
1.71 
(1.46,1.99) 
Vinturache et 
al 2014 52 
1.19 
(1.12,1.26) 
0.80 
(0.74,0.88) 
1 1.24 
(1.15,1.34) 
1.42 
(1.27,1.59) 
1.55 
(1.37,1.76) 
1.65 
(1.44,1.89) 
1.75 
(1.50,2.05) 
Voigt et al 
2008 53 
1.20 
(1.12,1.28) 
0.80 
(0.73,0.87) 
1 1.25 
(1.15,1.35) 
1.43 
(1.28,1.60) 
1.57 
(1.37,1.80) 
1.71 
(1.45,2.02) 
No data 
Yazdani et al 
2012 54 
1.19 
(1.12,1.27) 
0.80 
(0.74,0.87) 
1 1.25 
(1.15,1.35) 
1.43 
(1.28,1.60) 
1.56 
(1.38,1.77) 
1.66 
(1.45,1.91) 
1.76 
(1.50,2.06) 
Footnote: Sensitivity analyses were performed by excluding one study at a time from the meta
analysis to identify the effect of any one individual study. The summary OR per 5 BMI units, obtained 
in the linear doseresponse analysis, ranged from 1.16 (1.10,1.24) when the study by Kitiyodom et 
al31 was removed to 1.20 (1.12,1.28) when either of the studies by Kashan et al29 and Voigt et al53 
were excluded. Consistently, for the nonlinear analysis the lowest ORs for all overweight and obese 
BMI midpoints resulted from the exclusion of the study by Kitiyodom et al31. Abbreviations: NA = not 
applicable as study was excluded from nonlinear analysis for reporting only 2 BMI categories. 
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Table S9: Maternal BMI and post4term birth ≥ 41 weeks sensitivity analysis  
 
 Linear 
analyses  
OR  
(95% CI) 
Nonlinear Analyses: BMI Midpoint (kg/m
2
) 
OR (95% CI) 
Model 5 BMI 
units 
17.5 22.5 27.5 32.5 37.5 42.5 
Arrowsmith et 
al 2011 19 
1.10 
(1.05,1.15) 
0.87 
(0.77,0.97) 
1 1.08 
(1.05,1.11) 
1.05 
(0.99,1.11) 
0.94 
(0.76,1.17) 
0.82 
(0.54,1.25) 
Basu et al 
2010 20 
1.12 
(1.05,1.18) 
0.84 
(0.75,0.94) 
1 1.13 
(1.07,1.19) 
1.15 
(1.04,1.26) 
1.08 
(0.87,1.34) 
0.99 
(0.67,1.45) 
Halloran et al 
2012 27 
1.13 
(1.04,1.22) 
0.82 
(0.73,0.92) 
1 1.13 
(1.07,1.20) 
1.13 
(0.98,1.30) 
1.02 
(0.73,1.41) 
0.87 
(0.50,1.54) 
Leung et al 
2008 34 
1.12 
(1.05,1.19) 
0.84 
(0.75,0.95) 
1 1.13 
(1.06,1.21) 
1.17 
(1.07,1.28) 
1.12 
(0.91,1.38) 
1.04 
(0.71,1.53) 
Lumme et al 
1995 
35
 
1.10 
(1.04,1.16) 
0.91 
(0.85,0.97) 
1 1.11 
(1.04,1.20) 
1.22 
(1.07,1.39) 
1.33 
(1.10,1.59) 
1.43 
(1.13,1.83) 
Manzanares 
et al 2012 37 
1.14 
(1.07,1.21) 
0.84 
(0.76,0.94) 
1 1.14 
(1.08,1.21) 
1.19 
(1.09,1.31) 
1.17 
(0.95,1.43) 
1.10 
(0.76,1.60) 
Nohr et al 
2009 40 
1.12 
(1.05,1.19) 
0.84 
(0.75,0.93) 
1 1.13 
(1.07,1.20) 
1.15 
(1.05,1.27) 
1.09 
(0.87,1.35) 
0.99 
(0.66,1.46) 
Schrauwers et 
al 2009 46 
1.12 
(1.05,1.18) 
0.85 
(0.76,0.94) 
1 1.12 
(1.07,1.19) 
1.15 
(1.05,1.27) 
1.11 
(0.90,1.36) 
1.02 
(0.71,1.49) 
ScottPilai et 
al 2013 47 
1.13 
(1.05,1.22) 
0.83 
(0.74,0.94) 
1 1.14 
(1.06,1.22) 
1.16 
(1.01,1.32) 
1.08 
(0.83,1.43) 
0.98 
(0.61,1.57) 
Stotland et al 
2007 49 
1.10 
(1.04,1.17) 
0.86 
(0.76,0.96) 
1 1.11 
(1.07,1.16) 
1.14 
(1.07,1.22) 
1.09 
(0.89,1.34) 
1.01 
(0.69,1.50) 
Vaswani et al 
2013 51 
1.11 
(1.05,1.18) 
0.84 
(0.76,0.94) 
1 1.12 
(1.06,1.18) 
1.14 
(1.04,1.25) 
1.08 
(0.87,1.34) 
0.98 
(0.66,1.45) 
Footnote: Sensitivity analyses were performed by excluding one study at a time from the meta
analysis to identify the effect of any one individual study. The summary OR per 5 BMI units, obtained 
in the linear doseresponse analysis, ranged from 1.10 (1.04,1.16) when the study by Lumme et al35 
was excluded to 1.13 (1.05,1.22) when the study by ScottPilai et al47 was excluded. In the nonlinear 
analysis, the biggest change on the ORs for all BMI midpoints occurr when excluding the study by 
Lumme et al35 resulting in a linear association between maternal BMI and prolonged pregnancy (fig. 
S5).  
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Figure S5: Nonlinear dose4response analysis for maternal BMI and post4term 
birth ≥41 weeks, including all studies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Legend: Nonlinear metaanalysis for postterm ≥41 weeks when including Lumme et al35 study data. 
Despite the nonlinear appearance of the graph, linearity is not rejected (p = 0.065, table S6). 
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Table S10: Meta4regression and sub4group results for post4term birth ≥ 42 
weeks 
 Variable   Effect and Significance Heterogeneity Results 
 Subgroup 
n 
studies OR 
Lower 
95% CI 
Upper 
95% CI 
Sub4group 
specific 

 (%) p value 
Meta4
regression 

 
(%) 
All studies 19 1.18 1.11 1.26 <0.001  98.1 
Clinical Factors 
Assessment of 
BMI             96.12 
   Selfreported 9 1.143 1.075 1.215 91.3 <0.001   
   Measured 10 1.206 1.122 1.297 97.5 <0.001   
Unclear 0             
Assessment of 
Gestational Age             98.2 
   Selfreported 
(LMP) 2 1.377 0.964 1.967 88.2 0.004   
   Measured (USS) 12 1.184 1.095 1.281 98.8 <0.001   
Unclear 5 1.09 1.068 1.113 0 0.76   
Induction of 
Labour or 
Caesarean 
Section 4 
adjusted             94.63 
   Yes 3 1.301 1.289 1.313 0 0.651   
   No 16 1.155 1.095 1.218 95.4 <0.001   
Parity 4 adjusted             93.79 
   Yes 4 1.237 1.154 1.325 98.3 <0.001   
   No 13 1.129 1.071 1.191 87.4 <0.001   
   Primiparous only 2 1.214 1.134 1.3 0 0.472   
Gestational 
diabetes 4 
adjusted             96.85 
   Yes 4 1.196 0.952 1.503 87 <0.001   
   No 14 1.188 1.12 1.259 97.4 <0.001   
   Unclear 1 1.011 0.655 1.56       
Hypertension / 
Pre4eclampsia 4 
adjusted             98.31 
   Yes 3 1.385 1.131 1.696 56.4 0.101   
   No 15 1.161 1.086 1.24 98.6 <0.001   
   Unclear 1 1.011 0.655 1.56       
Methodology/context of included studies 
Geographic 
location             96.79 
   Europe 11 1.148 1.079 1.222 97.9 <0.001   
   North America 4 1.158 0.972 1.378 87.4 <0.001   
   Asia 4 1.42 1.066 1.892 73.1 0.011   
Study Quality 
score             94.87 
   02 2 1.087 1.065 1.11 0 0.89   
   35 15 1.168 1.098 1.242 95.7 <0.001   
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 Variable   Effect and Significance Heterogeneity Results 
 Subgroup 
n 
studies OR 
Lower 
95% CI 
Upper 
95% CI 
Sub4group 
specific 

 (%) p value 
Meta4
regression 

 
(%) 
   68 2 1.301 1.289 1.313 0 0.528   
Study dimension             95.97 
   Local 6 1.19 0.988 1.432 86.5 <0.001   
   Regional 8 1.133 1.059 1.212 86.4 <0.001   
   National 5 1.181 1.093 1.275 98.8 <0.001   
Study start (per 
decade)             96.29 
1970 1 1.219 1.138 1.307       
1980 3 1.018 0.813 1.274 84.3 0.002   
1990 6 1.203 1.125 1.287 98.5 <0.001   
2000 8 1.17 1.074 1.275 86.8 <0.001   
2010 1 1.011 0.655 1.56       
Type of study             98.22 
   Retrospective 13 1.185 1.108 1.267 98.8 <0.001   
   Prospective 6 1.17 0.882 1.552 79.9 <0.001   
Sample Size             98.33 
   <1000 10 1.216 1.019 1.452 79.3 <0.001   
   1000<10000 4 1.204 1.145 1.267 48.7 0.119   
   >=10000 5 1.122 1.016 1.239 99.6 <0.001   
Number of cases             98.33 
   <100 7 1.124 0.818 1.545 76.4 <0.001   
   100<1000 4 1.344 1.147 1.575 83 0.001   
   1000<10000 4 1.142 1.05 1.241 92.5 <0.001   
   >10000 4 1.144 1.024 1.277 99.6 <0.001   
Number of 
Exposure 
Categories             75.95 
2 2 1.095 0.373 3.213 86.9 0.006   
3 3 1.09 1.068 1.113 0 0.421   
4 4 1.282 1.211 1.358 29.9 0.233   
5 5 1.217 1.152 1.284 80.5 <0.001   
6 5 1.092 1.027 1.16 84.9 <0.001   
Methodology of this systematic review 
Publication 
Decade             98.18 
   1990s 2 0.896 0.515 1.559 91.4 0.001   
   2000s 10 1.199 1.14 1.262 93.7 <0.001   
   2010s 7 1.145 0.959 1.366 99.2 <0.001   
Study 
Identification             98.18 
   Citation Search 4 1.25 0.828 1.888 74.1 0.009   
   Database 
Search 12 1.2 1.115 1.291 98.8 <0.001   
Reference List 
Search 3 1.029 0.885 1.196 83.5 0.002   
Adjustment of 
the odds ratios       93.8 
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 Variable   Effect and Significance Heterogeneity Results 
 Subgroup 
n 
studies OR 
Lower 
95% CI 
Upper 
95% CI 
Sub4group 
specific 

 (%) p value 
Meta4
regression 

 
(%) 
Unadjusted 15 1.141 1.084 1.202 87.6 <0.001  
Adjusted 4 1.237 1.154 1.325 98.3 <0.001  
Footnote: Highlighted data show the results of the subgroup metaanalyses which resulted in a lack 
of statistically significant heterogeneity (<75%, p>0.05) when three or more studies were included in 
the metaanalysis. Abbreviations	 = number of studies,  = odds ratio,  !" = 
lower limit of the 95% confidence interval, ## !" = upper limit of the 95% confidence interval, 
LMP = last menstrual period, USS = ultrasound scan 
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Table S11: Meta4regression and sub4group results for post4term birth ≥ 41 
weeks 
 
 Variable   Effect and Significance Heterogeneity Results 
Subgroup 
n 
studies OR 
Lower 
95% CI 
Upper 
95% CI 
Sub4group 
specific 

 (%) p value 
Meta4
regression 

 
(%) 
All studies 11 1.13 1.06 1.21 <0.001  94 
Clinical Factors 
Assessment of BMI             89.54 
   Selfreported 3 1.14 0.987 1.317 94.8 <0.001   
   Measured 8 1.119 1.022 1.225 86.2 <0.001   
   Not available 0             
Assessment of 
Gestational Age             94.3 
   Selfreported (LMP)  0             
   Measured (USS) 4 1.176 1.036 1.335 97.8 <0.001   
   Not available 7 1.09 0.989 1.201 79.6 <0.001   
Induction of Labour or 
Caesarean Section 4 
adjusted             83.51 
   Yes 3 1.166 1.025 1.328 91.6 <0.001   
   No 8 1.103 1.033 1.178 78.9 <0.001   
Parity 4 adjusted             83.51 
   Yes 3 1.166 1.025 1.328 91.6 <0.001   
   No 8 1.103 1.033 1.178 78.9 <0.001   
   Primiparous only 0             
Gestational diabetes 4 
adjusted             94.86 
   Yes 5 1.145 1.024 1.281 97.2 <0.001   
   No 5 1.104 0.947 1.287 81.2 <0.001   
   Unclear 1 1.105 1.046 1.167       
Hypertension / Pre4
eclampsia 4 adjusted             83.21 
   Yes 4 1.178 1.057 1.313 87.3 <0.001   
   No 6 1.089 0.989 1.199 80.7 <0.001   
   Unclear 1 1.105 1.046 1.167       
Methodology/context of included studies 
Geographic location             92.77 
   Europe 5 1.095 0.962 1.246 91.5 <0.001   
   North America 2 1.164 0.938 1.444 97.4 <0.001   
   Asia 2 1.129 1.041 1.224 27 0.242   
  Africa 1 1.131 0.959 1.335       
  Australia 1 1.172 0.528 2.602       
Study Quality score             85.32 
   02 1 1.172 0.528 2.602       
   35 7 1.103 1.032 1.179 81.9 <0.001   
   68 3 1.166 1.025 1.328 91.6 <0.001   
Study dimension             87.05 
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 Variable   Effect and Significance Heterogeneity Results 
Subgroup 
n 
studies OR 
Lower 
95% CI 
Upper 
95% CI 
Sub4group 
specific 

 (%) p value 
Meta4
regression 

 
(%) 
   Local 7 1.151 1.058 1.252 84.1 <0.001   
   Regional 2 1.169 0.928 1.474 94.6 <0.001   
   National 1 1.093 0.995 1.2       
Study start (per 
decade)             94.18 
   1980 1 1.324 1.189 1.475       
   1990 3 1.164 1.039 1.305 87 <0.001   
   2000 6 1.054 0.948 1.172 95.5 <0.001   
   2010 1 1.223 1.041 1.436       
Type of study             94.05 
   Retrospective 9 1.108 1.022 1.202 94.7 <0.001   
   Prospective 2 1.201 0.994 1.45 85.7 0.008   
Sample Size             94.87 
   <1000 2 1.133 0.963 1.333 0 0.932   
   1000<10000 4 1.121 0.952 1.32 86.6 <0.001   
   >=10000 5 1.127 1.021 1.244 97.1 <0.001   
Number of cases             87.19 
   <100 1 1.172 0.528 2.602       
   100<1000 5 1.123 0.982 1.284 82.1 <0.001   
   1000<10000 4 1.152 1.043 1.272 91.3 <0.001   
   >10000 1 1.046 1.037 1.054       
Number of Exposure 
Categories             92.68 
  4 4 1.288 1.219 1.361 0 0.428   
  5 2 1.129 1.041 1.224 27 0.242   
  6 5 1.049 0.948 1.162 96.4 <0.001   
Methodology of this systematic review 
Publication Decade             93.51 
   1990s 1 1.324 1.189 1.475     
   2000s 4 1.165 1.045 1.298 80.5 0.002   
   2010s 6 1.074 0.972 1.186 95.6 <0.001   
Study Identification             94.23 
   Citation Search 1 0.893 0.784 1.017       
   Database Search 8 1.132 1.046 1.224 95.2 <0.001   
Reference List Search 2 1.322 1.188 1.47 0 0.766   
Adjustment of the odds 
ratios       82.42 
Unadjusted 7 1.091 1.020 1.168 79.8 <0.001  
Adjusted 4 1.178 1.057 1.313 87.3 <0.001  
Footnote: Highlighted data show the results of the subgroup metaanalyses which resulted in a lack 
of statistically significant heterogeneity (<75%, p>0.05) when three or more studies were included in 
the metaanalysis. Abbreviations	 = number of studies,  = odds ratio,  !" = 
lower limit of the 95% confidence interval, ## !" = upper limit of the 95% confidence interval, 
LMP = last menstrual period, USS = ultrasound scan  
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Yes, the following relationships/conditions/circumstances are present (explain below):
No other relationships/conditions/circumstances that present a potential conflict of interest ✔
 Relationships not covered aboveSection 5.
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. 
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form and is responsible for the accuracy and completeness of the submitted information.  The form is in six parts. 
              Identifying information.   
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without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that 
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give the appearance of potentially influencing, what you wrote in the submitted work.  You should disclose interactions with ANY entity 
that could be considered broadly relevant to the work.  For example, if your article is about testing an epidermal growth factor receptor 
(EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer 
in general, not just in the area of EGFR or lung cancer. 
Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to 
submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the 
entity that sponsored the research.  Please note that your interactions with the work's sponsor that are outside the submitted work 
should also be listed here.  If there is any question, it is usually better to disclose a relationship than not to do so.  
 For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be 
perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be 
perceived to have a financial stake in the outcome.  Public funding sources, such as government agencies, charitable foundations or 
academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved 
and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.  
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This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties. 
Relationships not covered above.  
Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of 
potentially influencing, what you wrote in the submitted work. 
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patent
Entity: government agency, foundation, commercial sponsor, 
academic institution, etc.  
Grant:  A grant from an entity, generally [but not always] paid to your 
organization 
Personal Fees: Monies paid to you for services rendered, generally 
honoraria, royalties, or fees for consulting , lectures, speakers bureaus, 
expert testimony, employment, or other affiliations  
Non-Financial Support: Examples include drugs/equipment 
supplied by the entity, travel paid by the entity, writing assistance, 
administrative support, etc.
3DJHRI
:RUOG2EHVLW\-RXUQDOV
2EHVLW\5HYLHZV




























































)RU3HHU5HYLHZ
ICMJE Form for Disclosure of Potential Conflicts of Interest 
2Crowe
 Identifying Information Section 1.
1.  Given Name (First Name)
Lisa
2.  Surname (Last Name) 
Crowe
4.  Are you the corresponding author? Yes No✔
3.  Date
27-July-2016
Corresponding Author’s Name
Nicola Heslehurst
5.  Manuscript Title
Maternal body mass index and post-term birth: a systematic review and meta-analysis
6.  Manuscript Identifying Number (if you know it)
The Work Under Consideration for PublicationSection 2.
Did you or your institution at any time receive payment or services from a third party (government, commercial, private foundation, etc.) for 
any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, 
statistical analysis, etc.)?
Are there any relevant conflicts of interest? Yes No✔
            
Relevant financial activities outside the submitted work.Section 3. 
Are there any relevant conflicts of interest? Yes No✔
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount 
of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by 
clicking the "Add +" box. You should report relationships that were present during the 36 months prior to publication.
            
Intellectual Property -- Patents & CopyrightsSection 4. 
Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes No✔
3DJHRI
:RUOG2EHVLW\-RXUQDOV
2EHVLW\5HYLHZV




























































)RU3HHU5HYLHZ
ICMJE Form for Disclosure of Potential Conflicts of Interest 
3Crowe
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of 
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No other relationships/conditions/circumstances that present a potential conflict of interest ✔
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The purpose of this form is to provide readers of your manuscript with information about your other interests that could 
influence how they receive and understand your work. The form is designed to be completed electronically and stored 
electronically.  It contains programming that allows appropriate data display.  Each author should submit a separate 
form and is responsible for the accuracy and completeness of the submitted information.  The form is in six parts. 
              Identifying information.   
            The work under consideration for publication.  
This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the 
work itself, from the initial conception and planning to the present. The requested information is about resources that you received, 
either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work 
without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that 
pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds 
from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check 
"Yes".   
          Relevant financial activities outside the submitted work.   
This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that 
give the appearance of potentially influencing, what you wrote in the submitted work.  You should disclose interactions with ANY entity 
that could be considered broadly relevant to the work.  For example, if your article is about testing an epidermal growth factor receptor 
(EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer 
in general, not just in the area of EGFR or lung cancer. 
Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to 
submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the 
entity that sponsored the research.  Please note that your interactions with the work's sponsor that are outside the submitted work 
should also be listed here.  If there is any question, it is usually better to disclose a relationship than not to do so.  
 For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be 
perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be 
perceived to have a financial stake in the outcome.  Public funding sources, such as government agencies, charitable foundations or 
academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved 
and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.  
            Intellectual Property.  
This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties. 
Relationships not covered above.  
Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of 
potentially influencing, what you wrote in the submitted work. 
Definitions.
Instructions
1.
2.
3.
4.
5.
Other: Anything not covered under the previous three boxes  
Pending:  The patent has been filed but not issued  
Issued:  The patent has been issued by the agency   
Licensed: dŚĞƉĂƚĞŶƚŚĂƐďĞĞŶůŝĐĞŶƐĞĚƚŽĂŶĞŶƚŝƚǇ͕ǁŚĞƚŚĞƌ
ĞĂƌŶŝŶŐƌŽǇĂůƚŝĞƐŽƌŶŽƚ 
ZŽǇĂůƚŝĞƐ͗Funds are coming in to you or your institution due to your 
patent
Entity: government agency, foundation, commercial sponsor, 
academic institution, etc.  
Grant:  A grant from an entity, generally [but not always] paid to your 
organization 
Personal Fees: Monies paid to you for services rendered, generally 
honoraria, royalties, or fees for consulting , lectures, speakers bureaus, 
expert testimony, employment, or other affiliations  
Non-Financial Support: Examples include drugs/equipment 
supplied by the entity, travel paid by the entity, writing assistance, 
administrative support, etc.
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27-July-2016
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Did you or your institution at any time receive payment or services from a third party (government, commercial, private foundation, etc.) for 
any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, 
statistical analysis, etc.)?
Are there any relevant conflicts of interest? Yes No✔
            
Relevant financial activities outside the submitted work.Section 3. 
Are there any relevant conflicts of interest? Yes No✔
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount 
of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by 
clicking the "Add +" box. You should report relationships that were present during the 36 months prior to publication.
            
Intellectual Property -- Patents & CopyrightsSection 4. 
Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes No✔
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Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of 
potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
No other relationships/conditions/circumstances that present a potential conflict of interest ✔
 Relationships not covered aboveSection 5.
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. 
On occasion, journals may ask authors to disclose further information about reported relationships. 
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box 
below.
Disclosure StatementSection 6.
Mr. Jones has nothing to disclose.
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The purpose of this form is to provide readers of your manuscript with information about your other interests that could 
influence how they receive and understand your work. The form is designed to be completed electronically and stored 
electronically.  It contains programming that allows appropriate data display.  Each author should submit a separate 
form and is responsible for the accuracy and completeness of the submitted information.  The form is in six parts. 
              Identifying information.   
            The work under consideration for publication.  
This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the 
work itself, from the initial conception and planning to the present. The requested information is about resources that you received, 
either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work 
without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that 
pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds 
from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check 
"Yes".   
          Relevant financial activities outside the submitted work.   
This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that 
give the appearance of potentially influencing, what you wrote in the submitted work.  You should disclose interactions with ANY entity 
that could be considered broadly relevant to the work.  For example, if your article is about testing an epidermal growth factor receptor 
(EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer 
in general, not just in the area of EGFR or lung cancer. 
Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to 
submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the 
entity that sponsored the research.  Please note that your interactions with the work's sponsor that are outside the submitted work 
should also be listed here.  If there is any question, it is usually better to disclose a relationship than not to do so.  
 For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be 
perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be 
perceived to have a financial stake in the outcome.  Public funding sources, such as government agencies, charitable foundations or 
academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved 
and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.  
            Intellectual Property.  
This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties. 
Relationships not covered above.  
Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of 
potentially influencing, what you wrote in the submitted work. 
Definitions.
Instructions
1.
2.
3.
4.
5.
Other: Anything not covered under the previous three boxes  
Pending:  The patent has been filed but not issued  
Issued:  The patent has been issued by the agency   
Licensed: dŚĞƉĂƚĞŶƚŚĂƐďĞĞŶůŝĐĞŶƐĞĚƚŽĂŶĞŶƚŝƚǇ͕ǁŚĞƚŚĞƌ
ĞĂƌŶŝŶŐƌŽǇĂůƚŝĞƐŽƌŶŽƚ 
ZŽǇĂůƚŝĞƐ͗Funds are coming in to you or your institution due to your 
patent
Entity: government agency, foundation, commercial sponsor, 
academic institution, etc.  
Grant:  A grant from an entity, generally [but not always] paid to your 
organization 
Personal Fees: Monies paid to you for services rendered, generally 
honoraria, royalties, or fees for consulting , lectures, speakers bureaus, 
expert testimony, employment, or other affiliations  
Non-Financial Support: Examples include drugs/equipment 
supplied by the entity, travel paid by the entity, writing assistance, 
administrative support, etc.
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4.  Are you the corresponding author? Yes No✔
3.  Date
27-July-2016
Corresponding Author’s Name
Nicola Heslehurst
5.  Manuscript Title
Maternal body mass index and post-term birth: a systematic review and meta-analysis
6.  Manuscript Identifying Number (if you know it)
The Work Under Consideration for PublicationSection 2.
Did you or your institution at any time receive payment or services from a third party (government, commercial, private foundation, etc.) for 
any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, 
statistical analysis, etc.)?
Are there any relevant conflicts of interest? Yes No✔
            
Relevant financial activities outside the submitted work.Section 3. 
Are there any relevant conflicts of interest? Yes No✔
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount 
of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by 
clicking the "Add +" box. You should report relationships that were present during the 36 months prior to publication.
            
Intellectual Property -- Patents & CopyrightsSection 4. 
Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes No✔
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Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of 
potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
No other relationships/conditions/circumstances that present a potential conflict of interest ✔
 Relationships not covered aboveSection 5.
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. 
On occasion, journals may ask authors to disclose further information about reported relationships. 
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box 
below.
Disclosure StatementSection 6.
Ms. Robalino has nothing to disclose.
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Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.
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The purpose of this form is to provide readers of your manuscript with information about your other interests that could 
influence how they receive and understand your work. The form is designed to be completed electronically and stored 
electronically.  It contains programming that allows appropriate data display.  Each author should submit a separate 
form and is responsible for the accuracy and completeness of the submitted information.  The form is in six parts. 
              Identifying information.   
            The work under consideration for publication.  
This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the 
work itself, from the initial conception and planning to the present. The requested information is about resources that you received, 
either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work 
without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that 
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